Bulgarian Algorithm for Diagnosis and Treatment of Multiple Sclerosis

Edited by Acad. Prof. I. Milanov, MD, PhD, DSc

Sofia, 23 January 2018

Initiative of:
Movement Disorders and Multiple Sclerosis Society
Bulgarian Society of Neurology
NATIONAL CONSENSUS STATEMENT FOR DIAGNOSIS AND TREATMENT OF
MULTIPLE SCLEROSIS

Today, we, the undersigned experts have reached a consensus on the diagnosis and treatment
of multiple sclerosis

Acad. Prof. Ivan Milanov

Corr. member Prof. Latechezar Traikov

Prof. Ivaylo Tarnev

Prof. Paraskeva Stamenova

Prof. Marin Daskalov

Prof. Veneta Bojinova

Prof. Dimitar Maslarov

Prof. Zahari Zahariev

Prof. Ara Kaprelyan

Prof. Lyubomir Haralanov

Prof. Krasimir Genov

Prof. Maria Manova

Assoc. Prof. Sonya Ivanova

Assoc. Prof. Dimitar Georgiev

Assoc. Prof. Desislava Bogdanova
Multiple sclerosis (MS) is an autoimmune disease with genetic predisposition, which in combination with environmental factors, triggers a cascade of immune responses and leads to disturbances of the blood-brain barrier. The result is an inflammatory demyelination of the white brain matter in the central nervous system (CNS), involving T- and B-lymphocytes, and macrophages. The transmission disturbances in CNS signals lead to clinical neurologic deficit.

The worldwide incidence and prevalence of MS varies with geographic and racial differences. The greatest incidence tends to be in Northern geographic regions and in subjects with Caucasian ancestry.

The prevalence of MS in Bulgaria is 44.5/100,000, and the incidence is 1.03/100,000 population, which means that nearly 3,600 people in Bulgaria suffer from MS and each year 80 new patients are diagnosed. The statistical data presented is from 1997 and differs from that in neighboring countries or high-risk Central European regions, where prevalence rate exceeds 100/100,000 population. The increase in prevalence and incidence is probably due to better and earlier detection. Assuming a two-fold increase in rates, the number of MS patients in Bulgaria is approximately 7,000 – with approximately 160 new diagnosed patients each year.

The disease affects primarily young people aged between 30-34 years. In 3-10% of MS cases, the onset occurs in childhood and adolescence. Women are affected approximately twice as often as men. MS is a chronic disease, with duration of 10 to 15 years (13 years on average) depending on the clinical course of the disease.

MS is classified into 3 clinical forms depending on the clinical course of the disease over time (Appendix 1). The 2013 International MS Phenotype Group revisions further characterise the MS phenotypes, and differentiate between patients eligible for treatment with active inflammation (new relapses and/or new MRI activity) from those with declining and irreversible disability progression.

Relapsing-remitting MS (RRMS) is the most common course for the disease – in 85% of patients (approximately 5,950 patients in Bulgaria), and RRMS is characterised by clearly defined attacks of neurologic dysfunction (relapses) followed by several weeks of slow recovery (partial or complete). Subsequent attacks (exacerbations) occur at irregular intervals of time. However, there is no apparent progression of the disease between relapses. This clinical pattern of the disease includes cases with relapses and cumulative damage due to incomplete recovery, although they are difficult to distinguish from secondary-progressive MS. For 62% of patients (approximately 4,340 patients in Bulgaria) the disability score according to Kurtzke Expanded Disability Status Scale (EDSS) is less than 5 points.

In secondary-progressive MS gradually accumulating irreversible disability with or without separate relapses, minor remissions and plateaus have been observed. 70% of patients with RRMS
would transition into the secondary progressive form of MS (SPMS) within 6 to 10 years from the onset of the disease. Although the time for transition to secondary progressive MS might be longer, when the onset of the disease is in childhood or adolescence, significant disability may be accumulated, and the patient will be disabled about 10 years earlier compared to adult patients.

**Primary progressive MS** affects a relatively small number of patients (10%). It is characterised with a steady and slow decline in neurological symptoms and deficit from the beginning, without clearly defined relapses or remissions, although occasional plateaus and temporary minor improvement might be observed. Compared with the remitting-relapsing form, PPMS is associated with early severe disability, less number of lesions on MRI and prevalence of degeneration over inflammation. Immunogenic differences have been established, such as higher incidence of HLA-DR4 positive patients compared to RRMS patients.

Depending on the degree and rate of neurological decline, MS is further subdivided into benign and malignant forms.

Diagnosis of benign forms is retrospective, when 15 years from disease onset the rate and severity of relapses and progressing neurological deficit are much milder compared to those in other patient groups. The benign form of the disease is characterised by mild disability and the patient remains relatively fully functional. However, disability associated with cognitive impairment, fatigue, depression, and pelvis floor disorders is often disregarded in such patients. A diagnosis of benign PPMS changes over time. Ten years after diagnosis 1/3 of patients have a benign MS phenotype, while their number decreases to only 1/5 after 20 years.

**Malignant MS** is observed in a small number of patients. The disease develops quickly with frequent relapses and continuous disability progression leading to quick severe neurological deficit (within months or several years).

**The clinical course** is characterised with occasional transient or progressive neurological decline (pyramidal symptoms, co-ordination and balance disturbances, sensory or pelvic floor disorders).

Disease onset is often manifested with vision disorders or eye movement abnormalities (in 49% of patients), followed by limb paresis or paresthesia (42%), coordination disturbances (23%), or pelvic floor disorders (10%). Symptoms may be isolated or may occur concomitantly (in 30-50% of patients). Initial manifestations, such as vertigo, trigeminal neuralgia, paroxysmal symptoms, extrapyramidal motor dysfunction or dysarthria, are less common (5%).

Over the course of the disease, all patients develop vision disorders or eye movement abnormalities, paresis or paresthesia in the arms and legs (88%), coordination disturbances (82%), pelvic floor disorders (63%) or cognitive impairments (40%).
A relapse is diagnosed using certain criteria. Pseudo-relapse (periods of exacerbations), triggered by concomitant diseases, fever or infection should be excluded. The interval between relapses is defined as the time of onset of one relapse to the beginning of the next one.

### Criteria for onset of a new relapse include:

- Appearance of a new neurological symptom
- Reappearance of an old neurological symptom
- Worsening of an existing symptom of > 0.5 point on the Kurtzke scale
- Duration > 24 hours
- Absence of fever or concomitant conditions
- A period of neurological stability or improvement for at least 30 days

The diagnosis is based on the 2010 revision of Polman et al. to the McDonald Criteria (Appendix 2). In the revisions instead of Barkhof/Tintore criteria for dissemination of MRI lesions in both space and time (DIS), the simplified criteria of Swanton et al., approved by the European collaborative research network studying MRI in MS (MAGNIMS), are used. In the MAGNIMS modifications the number of lesions required to define dissemination in time and space is reduced to a minimum. Gadolinium enhancement of lesions is no longer required to define dissemination in space (DIS), since it is a marker of dissemination in time and not in space. Specifically, in patients with brainstem or spinal cord syndromes, MRI lesions are not used for the total lesion count. According to the 2010 McDonald criteria, the co-presence of asymptomatic gadolinium-enhanced and non-enhanced lesions at any time is a criterion to define DIT, without a need for MRI follow-up to demonstrate DIT. Obviously the two demyelinating lesions have not appeared during the same demyelinating event, and their concomitant presence is indicative of 2 or more events occurring at different time points. However, a sound differential diagnosis is required to prove that the contrast-enhanced lesion is not induced by competing conditions. A major challenge is to distinguish typical MS lesions from lesions found in other conditions. In the absence of concomitant contrast-enhancing and non-enhancing lesions, a new clinical relapse should be awaited or further MRI be performed at any time.

According to the new criteria, cerebrospinal fluid testing and vision evoked potentials assessment are no longer required to support the diagnosis of relapsing-remitting MS. Patients, who are positive in both assessments, will have sufficient number of MRI lesions to define DIT as per the criteria. Cerebrospinal fluid testing is reserved to define primary-progressive MS and includes presence of CSF-specific oligoclonal bands only, but not quantitative assessment of intrathecal IgG synthesis.
The diagnostic criteria for primary-progressive multiple sclerosis include presence of 1 year of disease progression and new MRI criteria for DIS: presence of 2 out of 3 criteria – 1 T2 lesion in at least 1 typical MS area (periventricular, juxtacortical or infratentorial); – 2 or more T2 lesions in the spinal cord – positive CSF findings (oligoclonal bands and/or elevated IgG index).

The “multiple sclerosis”, “possible multiple sclerosis”, and “not multiple sclerosis” diagnostic categories are being used. Patients meeting all clinical criteria, will be diagnosed with multiple sclerosis. Failure to meet any of the MS diagnostic criteria, will result in a “possible MS” diagnosis. Where even part of the criteria is not met, the MS diagnosis will be ruled out.

The clinical diagnosis based on objective clinical evidence of two or more relapses can be more reliable. In some cases, patient-reported historical events with symptoms and evolution characteristics for MS, but for which no objective neurological findings are documented, might be reasonable evidence of a prior demyelinating event. However, at least 1 relapse should be confirmed by objective neurological findings. Before a definitive diagnosis of MS can be made, at least 1 relapse should be corroborated by objective findings from neurological examination, visual evoked potential response (in patients reporting visual disturbance), or results from MRI exam consistent with demyelination in affected area of the CNS further to neurological symptoms, reported by the patient.

With the new criteria, in the majority of cases MS is diagnosed as early as the first clinical signs, and symptoms which in practice reduces the number of patients with clinically isolated syndromes.

**Clinically isolated syndrome** (CIS) is the first clinical event that is compatible with any possible future development of multiple sclerosis but it is isolated in time. CIS symptoms are more pronounced when the three typical CNS regions are involved – the optic nerve, brainstem, and spinal cord. With the new diagnostic criteria, MRI was formally included in the diagnostic process of patients presenting with CIS.

**Radiologically isolated syndrome** refers to the presence of MRI anomalies suggesting multiple sclerosis, but without clinical symptoms. The increasing usage of MRI in daily practice has led to incidental identification of nonspecific T2 abnormalities, classified as “unidentified bright objects”. Some of these changes are highly suggestive of multiple sclerosis for their location (periventricular, corpus callosum) and morphology (ovoid, well defined, homogeneous). Patients with radiologically isolated syndrome are at high risk of deterioration of lesions on MRI within the following 3 years, and development of clinically isolated syndrome within 5 years. 80% of these patients progress to clinically definite multiple sclerosis.

In cases of complaints of limb weakness, loss of balance, visual disturbances due to retrobulbar neuritis, pelvic floor disorders or numbness in the limbs, in patients who are not diagnosed with
multiple sclerosis or manifestation of new symptoms in already diagnosed patients, the general practitioner should refer the patient without delay to a neurologist, multiple sclerosis specialist at a University center for diagnosis and management of multiple sclerosis (UCDM-MS).

The neurologist should clarify the diagnosis using the 2010 revisions of diagnostic criteria (Polman et al.), administer relevant laboratory tests and consultations, and admit the patient to UCDM-MS. The neurologist should also define the course of multiple sclerosis, and the annual number and the severity of MS relapses.

**Diagnostic methods** aim at an early diagnosis and the use of modern treatment methods. Early diagnosis of MS can be often challenging because the first manifestations are typically non-specific, mild, and quickly resolving. Currently, there is no specific laboratory test. Many medical conditions are associated with multifocal brain lesions on MRI or relapsing-remitting clinical symptoms in young age. 5% of these patients are misdiagnosed, meaning that 1 out of 20 patients does not actually have this disorder.

**Laboratory diagnostic methods include:**

1. **Ophthalmologic examination:** vision, fundus examination, perimetry. Temporal pallor of the optic disc is a typical symptom of preceding retrobulbar neuritis.

   **Optical coherence tomography** (OCT) provides evidence for atrophy or swelling in specific retinal layers. In optic neuritis and ganglion cell damage, the axonal retrograde degeneration leads to thinning of the retinal nerve fiber layer. The examination of the optic nerve can be used for assessment of CNS neurodegeneration. Several studies have reported a correlation between retinal changes and MS activity.

2. **Neurophysiological examinations:** visual, brainstem auditory, motor action, and somatosensory evoked potentials. Evoked potentials tests are used in the search for “silent” CNS lesions. Evoked potentials which can reveal subclinical lesions in CNS regions, but without clinical symptoms of damage, are tested. The changes in evoked potentials are expressed in prolonged latency, changes in wave amplitude and configuration, as well as interhemispheric asymmetries. In MS patients evoked potential tests very often show prolonged latency of components due to demyelination, but the changes are not disease-specific. Except for visual evoked potentials, the other tests also show changes in conditions in which axonal degeneration occurs first and degradation of myelin is secondary.

   The **visual evoked potentials (VEP)** test is of highest diagnostic value. It shows typical latency prolongation in the P100 wave with preserved wave configuration. In the presence of
clinically established vision damage the test is not justified. When a patient has had a negative VEP test, and the next testing shows typical latency prolongation, this might be suggestive of a new lesion.

3. Neuroimaging investigations – magnetic resonance imaging (MRI) is a modality of choice. The techniques include axial and parasagittal T₁, and T₂-weighted imaging, serial imaging, gadolinium-DTPA enhanced (Magnevist®) imaging and FLAIR sequencing.

In T₂-weighted imaging, hyperintensities (bright spots) are observed in patients in both early (with prevailing inflammation) and late stages (prevailing tissue damage and gliosis) of MS.

The number of lesions on MRI at different time points is compared by “disease burden” measuring – the total area of T2 lesions in mm².

In T₁-weighted imaging, hypointense lesions (also known as “black holes”) are detected, suggesting acute brain swelling or severe tissue damage. They correlate with the severity of clinical symptoms and are histopathologically consistent with a demyelination lesion with axonal damage and reactive gliosis. Chronic T₁ hypointense lesions (black holes) are more specific for severe tissue damage compared to T₂-weighted imaging abnormalities.

FLAIR imaging (fluid-attenuated inversion recovery) enhances contrast ratio between cerebrospinal fluid and lesions. This method allows better distinction between ventricular fluid (dark) and periventricular T2 lesions (bright) and increases contrast between lesions and CSF, especially contrast from cortical and juxtacortical lesions in the grey brain matter.

Gadolinium is a contrast agent, used to increase the sensitivity in T₁-weighted imaging. The most widely used agents in clinical practice are Magnevist® and a higher concentration agent Gadovist®, which improves imaging. Contrast provides information of increases of blood-brain barrier (BBB) permeability due to inflammation. Contrast agents typically do not cross BBB unless its permeability is increased. The examination is useful for distinguishing new lesions from old ones. The enhancement from Gadolinium correlates with inflammation and is observed in all new plaques. It lasts for 2 to 6 weeks and is consistent with the duration of relapse.

MRI diagnosis requires objective evidence of lesions disseminated in space (brain) and time – at least “open ring” pattern of contrast material enhancement of some lesions. MS lesions are typically located in corpus callosum, the periventricular or supratentorial brainstem regions, the cerebellum, and in the neck area of the spinal cord. They are usually ovoid in shape with size > 6 mm in diameter. The lesions should be larger than 3 mm in cross-sectional diameter and at least one of them should be larger than 5 mm. It should be considered that MRI detected lesions are typical, but not specific for MS. Gadolinium enhancement of lesions and presence of lesions in corpus callosum are prominent features, since they are not typical for vascular damage. Shape and orientation of lesions in corpus callosum are also important because in MS, inflammation affects vessels running perpendicular to corpus callosum. Ovoid elongated lesions resembling the fingers of the hand – the
so-called Dawson's fingers, are a classic sign of MS. The presence of T₂-hyperintense lesions in the spinal cord is specific for MS, because such lesions are not age-related. They should be at least 3 mm in diameter but should also extend over less than two spinal cord segments in length, and should not affect the entire transverse section of the spinal cord. The use of MRI findings alone as a stand-alone criterion for initiation, continuation, change or discontinuation of immune-modifying therapy in MS is not justified. There is moderate correlation among MS lesions on MRI, clinical findings, and clinical disability.

MRI lesions in children are more in number and larger in size, with more Gd-enhancing lesions and more frequent posterior fossa involvement.

Differential diagnosis of abnormal MRI findings in children should exclude other multifocal conditions manifested with hyperintense T₂-weighted lesions, but with different shape or location.

4. Cerebrospinal fluid analysis (general CFS parameters and electrophoresis) provides different type of information – i.e. about inflammation and immune disorders. It can be useful in patients with atypical clinical presentation or MRI lesions. The most specific finding is the presence of oligoclonal bands detected by agarose gel electrophoresis (AGE) or isoelectric-focusing. In patients with multiple sclerosis, the analysis shows two types of abnormalities in the cerebrospinal fluid, indicative of immune-mediated pathology:

1. Presence of oligoclonal bands of IgG, preferably detected by isoelectric-focusing. Found only in the CFS, but not in the serum (testing is mandatory) and present in 90% of MS patients. Once acquired, they persist throughout the whole life of MS patients.

2. Lymphocytic pleocytosis, which if present, should be higher than 50 WBC/mm³.

5. The testing for neutralizing antibodies (NAbs) to interferon-β therapy might help in guiding the choice and individualization of treatment strategies. NAbs appear 6 to 24 months after initiation of therapy. Persistent, high-titer neutralizing antibodies reduce the efficacy of IFN-β therapy. It is recommended that tests for the presence of NAbs should be performed 18 months after therapy initiation. In patients with persistent positive NAbs, switching to first or second-line therapies (depending on the disease activity) different from IFN-β therapies should be considered.

Not all diagnostic procedures are required but only those, which are sufficient to diagnose MS as per the revised diagnostic criteria. Depending on the facilities available, the procedures should be performed in the order indicated herein.

Differential diagnosis of multiple sclerosis requires exclusion of many conditions in which clinical presentation or laboratory test results are similar to those in MS. The diseases which should be considered in differential diagnosis of MS are:
1. Monophasic Demyelinating Disorders

Acute disseminated encephalomyelitis (ADEM) usually begins after a viral infection or vaccination. This monophasic inflammatory demyelinating condition is more common in children. It starts rapidly with acute onset of fever, general brain symptoms, multifocal neurological symptoms and epileptic seizures. MRI lesions can be identical to those in MS but more often are more extensive and poorly outlined. The level of albumin in CSF is elevated.

Transverse myelitis is an acute, monophasic disorder with symptoms of bilateral symmetrical damage below certain spinal cord level in contrast to the typical asymmetric involvement in multiple sclerosis. MRI of the brain is normal, while spinal cord MR imaging shows severe lesions.

Devic's syndrome (disease) (neuromyelitis optica) is characterised by a monophasic course and rare recurrent attacks, acute bilateral or unilateral optic neuritis, papilitis and subsequent development of myelitis and paraplegia. Most often occurs in children and young people at an average age of 25 years. MRI of the brain can show periventricular demyelinating lesions. Lesions extending over ≥ 3 vertebral segments in the central part of the spinal cord are detected. According to the Mayo clinic diagnostic criteria of 2010, the diagnosis neuromyelitis optica requires the presence of optic neuritis, acute myelitis and at least 2 of three additional criteria – adjacent spinal cord lesions on MRI extending over ≥ 3 vertebral segments, MRI negative/non-diagnostic for MS and NMO-IgG (AQP4) seropositivity.

Optic neuritis is a common initial manifestation of MS, so it should be distinguished from monosymptomatic MS. Patients with retrobulbar neuritis, who have MRI lesions, often develop MS within periods of varying length, while patients with normal MRI have better prognosis and may never develop MS. Optic neuritis is characterised by quick decrease in visual acuity in one or both eyes, retrobulbar pain, absence of visual brightness and colour vision and frequent central scotoma. Vision improves for a period of several weeks to several months. The visual disturbances are due to primary optic nerve demyelination and should be distinguished from secondary demyelination in optic neuropathy which mimics retrobulbar neuritis. Secondary optic nerve demyelination most often may result from compression, ischemia or toxic damage. Local viral, bacterial or fungal infections can also lead to optic nerve inflammation. Cases of post-viral and post-vaccination optic neuritis have been reported, as well as optic neuritis associated with collagenosis. Leber hereditary optic atrophy should be excluded.

Balo's concentric sclerosis is a variant of multiple sclerosis characterised by atypical lesions composed of alternate bands of demyelinated and myelinated white matter. A mixture of concentric white matter lesions and lesions typical for MS is found on MRI.

Schilder's disease (diffuse cerebral sclerosis) is associated with bilateral hemispheric demyelination in childhood. The clinical manifestations are aphasia, dementia, seizures and elevated
intracranial pressure. T2-weighted MRI shows large confluent areas of demyelination in the white matter.

2. Autoimmune Diseases

Behçet's disease is a multi-system inflammatory disease with CNS involvement. Optic nerves and spinal cord (myelon) are often affected. Typical manifestations are ulcers affecting the mucosa of the mouth cavity and the perineum. CSF and MRI findings are very similar to those in MS, but lesions in the deep grey matter and leptomeningeal changes are detected on MRI.

Systemic lupus erythematosus is a multi-organ autoimmune disease with fluctuating course. In 30% of patients, hyperintense lesions larger than 6 mm are detected on MRI, and elevated IgG levels, and in some cases – oligoclonality in CSF. Differential diagnosis is even more challenging in clinical presentations with myelopathy and vision disturbances. The presence of antinuclear antibodies (ANAs) is disease-specific but can also be found in 25% of MS patients.

Sjogren's syndrome is an autoimmune disease characterised by progressive damage of both salivary and lacrimal glands, and CNS involvement with clinical manifestations similar to those in MS in 25% of patients. The disease course is mostly relapsing-remitting, with multiple periventricular lesions on MRI and oligoclonal CSF bands. The differential diagnosis is guided by the presence of gland alterations, neuropathy, myositis and serological abnormalities.

Sarcoidosis is a multi-system granulomatous disorder affecting primarily the lymphoreticular system. 5% of patients experience symptoms of CNS origin. The disease course is relapsing-remitting and the first clinical manifestations can be neurological symptoms, such as cranial nerve lesions, visual disturbances and pyramidal symptoms. CSF analysis might show oligoclonality. MRI findings are consistent with MS, but detection of leptomeningeal enhancement is typical in gadolinium-based MRI.

3. Vascular Autoimmune Disorders

Antiphospholipid syndrome may manifest with progressive myelopathy, spinocerebellar injury or neuromyelitis optica syndrome. MRI findings show diffuse or confluent white matter lesions very similar to those in multiple sclerosis. Cerebrospinal fluid analysis shows normal cell counts and oligoclonal fractions in 15% of patients. The final diagnosis requires presence of IgG and IgM anticardiolipin antibodies and lupus anticoagulant testing.

Vasculitis can be characterised by multi-organ involvement or predominant involvement of the central nervous system. MRI shows infarction in cerebral grey matter. In vasculitis with primary CNS involvement, T2 lesions in periventricular and deep white matter are detected, very similar to
MS lesions. The diagnosis requires ESR testing, an antinuclear antibodies test, magnetic resonance angiography and brain biopsy.

**Sneddon's syndrome** is usually seen in younger adults and is characterised by onset of livedo reticularis and recurrent stroke-like episodes. A MRI typically shows multiple small white and gray matter lesions caused by strokes. The diagnosis requires testing for antiphospholipid antibodies, angiography and skin biopsy.

**Venous occlusive and cardioembolic disease** is observed in young people without vascular risk factors but with a family history of venous thrombosis. The disease course is characterised by intermittent focal neurological symptoms. Lesions on MRI are stroke-like and do not resemble those in multiple sclerosis apart from small white matter lesions. Testing for the presence of hypercoagulability and Doppler ultrasonography, and echocardiography are required. Results from CSF analysis are within reference range.

**4. Infectious Diseases**

**Progressive multifocal encephalopathy** is caused by JC virus infection in the central nervous system normally seen in immunocompromised individuals. Its course is characterised by continuous progression of cognitive, language and vision impairments. A fluctuating disease course resembling multiple sclerosis is rarer. T2-weighted MR imaging detects white matter, non-contrast enhancing lesions which are usually more confluent than those in multiple sclerosis. Final diagnosis is based on brain biopsy.

**Lyme disease** often manifests as neuroborreliosis with acute meningitis, cranial neuritis, myelopathy or encephalitis. MRI and spinal fluid changes are difficult to distinguish from those in MS. However, white matter T2-lesions are not periventricular. Antibodies to *Borrelia burgdorferi* have been detected, but they are not absolutely disease-specific and can also be observed in other inflammatory diseases of the central nervous system, including MS.

**Lues** (syphilis) also affects CNS causing optic neuritis, vasculitis, myelopathy and chronic encephalopathy, which makes the differential diagnosis a challenge. MRI findings depend on the stage of the disease and include infarction, nonspecific white matter lesions, chancres and meningeal enhancement. Diagnosis is based on the results of a serologic and CSF VDRL tests and microhemagglutination assay for *T. pallidum*.

**HIV-1 leukencephalopathy** is caused by the HIV-1 virus. This virus usually induces typical HIV-related neurocognitive disorders and more rarely milder recurrent disorders manifesting optic neuritis, myelopathy and cognitive dysfunction, which resemble those in multiple sclerosis. CNS complications often occur in the later stages of HIV infection, but in 10% of patients these are the presenting features of AIDS. MR imaging shows T2 lesions in the white matter which are confluent
and larger than those in multiple sclerosis. CSF analysis and evoked potentials testing show the same changes as in multiple sclerosis. Elevated levels of total protein and presence of abnormal cells in the CSF might be found but rarely in CSF with oligoclonal IgG bands. Diagnosis is based on positive HIV-1 serologic testing and low CD4 cell count.

5. Degenerative Diseases

Adrenoleukodystrophy (ALD) is a genetic disorder associated with accumulation of very long chain fatty acids (VLFA). The X-linked variant of ALD occurs in adolescents or adults and is characterised by progressive myelopathy and neuropathy, which in the absence of a family history, makes differential diagnosis a serious challenge. The course of the disease is relapsing-remitting or progressive, with manifestations of paraparesis, ataxia and cognitive disorders. Testing for VLFA in plasma may guide diagnosis, which is difficult because both CSF analysis and MR imaging show changes seen in MS.

Mitochondrial encephalopathy, with lactic acidosis and stroke-like episodes (MELAS) occurs in childhood. It is a hereditary disease characterised by external ophthalmoparesis, proximal muscle weakness and seizures. MRI findings include cortical and subcortical stroke-like lesions visible on T2-weighted MRI and FLAIR imaging. The final diagnosis requires analysis of CSF levels of lactate and pyruvate.

Leber hereditary optic neuropathy (LHON) is mainly characterised by bilateral subacute optic atrophy. It affects primarily adult males and is accompanied by myelopathy, ataxia and sensory disturbances. T2-weighted MR imaging detects white matter lesions identical to MS lesions. No CSF alterations are found. The diagnosis is confirmed after DNA testing.

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is associated with gene mutations in chromosome 19. The first symptoms occur between 30 and 50 years of age, with recurrent stroke-like episodes and subsequent development of dementia. MRI findings show multiple subcortical lesions. The diagnosis is built on the basis of CSF investigations within the normal range and genetic analysis.

Cerebellar atrophies (spinocerebellar ataxia, Friedreich's ataxia and olivopontocerebellar atrophy) are distinguished based on a family history, absence of remissions and normal CSF test results.

Vitamin B₁₂ (cobalamin) deficiency or dysmetabolism, a result of metabolic defects or acquired B₁₂ deficiency causes progressive myelopathy (especially with involvement of posterior and lateral columns of the spinal cord) and polyneuropathy. MRI shows transient T₂ hyperintensities in the cerebral white matter and spinal cord. The lesions disappear after correction of B₁₂ deficiency. The diagnosis is based on low vitamin B₁₂ levels in blood.
6. Spinal Cord Disorders

Arnold-Chiari malformation is associated with isolated spinal cord syndromes and involvement of the caudal cranial nerves and the cerebellum, ataxia and elevated intracranial pressure. MRI shows craniocervical junction abnormalities.

Myelopathy with progressive para- and quadriplegia in middle age should be distinguished from MS. Causes such as external or internal spinal cord compression, cervical spondylosis and vitamin B₁₂ deficiencies should be ruled out. MRI may prove the presence of spinal and cerebral lesions in MS.

Amyotrophic lateral sclerosis may cause diagnostic problems, because its early stages are characterised by absence of lower motor neuron signs and prominent upper motor neuron signs. MRI findings are normal. The diagnosis requires electromyographic evidence of multilevel injury of the anterior horn of spinal cord in at least 3 extremities.

The diseases to be considered in differential diagnosis can be divided into three main categories, depending on whether they have only clinical, clinical and MRI, or clinical, MRI and CFS features similar to those in MS.

Diseases which resemble MS in clinical presentation, but have different MRI findings:
1. Wegener's Granulomatosis;
2. Isolated spinal cord syndromes;
3. Compressive lesions;
4. B₁₂ deficiency;
5. Intracranial tumors;
6. Arnold Chiari malformation.

Diseases which resemble MS in clinical presentation and MRI criteria:
1. AIDS;
2. Cerebellar degenerations;
3. Mitochondrial encephalopathy;
4. Cerebrovascular disorders;
5. CADASIL.

Diseases which resemble MS in clinical presentation, MRI and CSF criteria:
1. Vasculitis:
   - Sjogren's syndrome;
   - Polyarthritis nodosa;
Systemic lupus erythematosus; Behçet's disease.

2. Lyme disease;
3. Sarcoidosis;
4. Adrenoleukodystrophy;
5. HTLV-1;
6. Leber hereditary optic atrophy;
7. Acute disseminated encephalomyelitis.

Treatment

The most important goal of treatment is to slow down disease progression and reduce long-term disability in MS patients. The choice of treatment differs depending on the disease course and whether the disease is in relapse phase or in remission. Treatment is generally divided into 3 main categories: management of relapses, disease-modifying therapy, and symptomatic management.

Management of relapses aims at rapid recovery of neurological symptoms experienced during the relapse. Exacerbations in relapsing-remitting multiple sclerosis prompt urgent intervention by a neurologist.

- In patients already diagnosed, the neurologist should determine whether the patient's condition is a relapse by using relevant criteria.
- In case of a new relapse, its severity should be determined in order to decide whether steroid therapy is indicated, or not.
- Mild relapses do not require steroid treatment. The patient should be closely monitored, and if the relapse is caused by an infection, the infection should be treated and the patient should be given non-steroid anti-inflammatory drugs for 1 to 2 weeks.
- The presence of acute and pronounced visual, motor and cerebellar symptoms or gate disturbances is an indication for corticosteroid treatment. In such cases immediate steroid therapy (Appendix 3) and symptomatic management (Appendix 4) in hospital settings is recommended depending on the relapse severity.
- Plasma exchange (plasmapheresis) is a second-line therapy for GCS-resistant relapses.

Glucocorticosteroids (GCS) are the most efficient therapy for relapse management. They are used as first-line therapy for management of relapses because of their anti-inflammatory and immunosuppressive effects and the ability to improve blood-brain barrier (BBB). Steroid treatment leads to reduction of activated T-lymphocytes with prevailing reduction of T-helper cells than T-suppressor cells. GCSs improve the tightness of the blood-brain barrier and affect the cascade of
immune responses leading to demyelination. Glucocorticosteroids, given in therapeutic doses, do not influence the disease course even with low-dose, long-term treatment. They only accelerate the neurologic recovery after relapse.

The different types of glucocorticosteroids differ in the ratio between glucocorticoid and undesirable mineralocorticoid activity.

Methylprednisolone is a first-line drug for relapse management because of its long biologic half-life of 18-36 hours, very good anti-inflammatory effect, weak mineralocorticoid activity and very good ability to cross the blood-brain barrier. It is used in doses from 500 to 1,000 mg daily (depending on the relapse severity), given intravenously in serum glucose for 3 to 5 days, but in refractory symptoms treatment can be extended to 10 days. Low-dose treatment is not recommended for their undesirable effects – frequent recurrences. Initial treatment is followed by the so-called dose tapering – injections or oral administration of lower doses. Dosage is adjusted in 10 to 12 days in increments of 10-20 mg every 3 days, starting from 80 mg daily. Dose tapering prevents reopening of the blood-brain barrier.

If a new relapse occurs soon (within days to weeks) after the end of steroid treatment, a second, shorter (3 days) course of steroids is recommended.

In patients with symptoms persisting for 8 to 12 weeks, steroid treatment can also be used but with a lesser effect.

In children methylprednisolone is used at a dose of 20 to 30 mg/kg daily administered intravenously as a single dose of 0.2 to 0.5 g (maximum 1g) daily in saline for 2 hours. Steroid treatment continues 4 to 6 days. The treatment is discontinued after complete recovery and in case of partial recovery the dose should be gradually tapered off with oral prednisone given every 2 to 3 days.

The side effects of steroid treatment include gastrointestinal disorders, ulcers, hypertension, arrhythmia, diabetes mellitus, various infections, osteoporosis, acne, thrombosis, mania, depression, etc. To avoid gastrointestinal side effects, preventive therapy with H₂-receptor antagonists (Ranitidine 300 mg/day twice daily administration, etc.) is recommended. During treatment, blood pressure can be controlled by changing the dosage of antihypertensive therapy (in hypertensive patients) or with diuretics and β-blockers. Blood pressure returns to normal following cessation of a steroid cycle. The onset of signs of mania, depression or acute psychotic symptoms requires discontinuation of steroid treatment and timely initiation of appropriate treatment (anxiolytic agents, neuroleptics, tranquilizers and antidepressants).

Use of ACTH (synthetic analogues Cortrosin®, Synacthen®) is not recommended because the mechanism of action is similar to that of glucocorticoids. The treatment effect of ACTH occurs more slowly (after 1 month) compared to that of methylprednisolone (after 1 week). Moreover, ACTH is
associated with more adverse effects, including allergies, which persist even after drug withdrawal, because of its prolonged effect.

**Plasmapheresis** is a procedure in which the patient's plasma is separated and removed from the blood. The removed amount of plasma is replaced with plasma substitute in a 1:1 ratio. It can be used for managing of recent acute and severe relapses with incomplete recovery of neurological symptoms after steroid treatment. The treatment consists of 7 procedures every 1-2 days with replacement of 54 ml/kg plasma with a mixture of 5% albumin and saline in each single session.

*Side effects* are hypotension, septicemia, bronchopneumonia, coagulation disturbances, central line complications and hypocalcemia.

**Treatment with disease-modifying drugs** is used in periods outside relapses to reduce the clinical and subclinical activity of the disease contributing to long-term disability. The choice of therapy depends on the disease course and activity. Currently, all drugs from this class are used in a *relapsing-remitting course* of the disease. Only interferon β-1b has proved effectiveness in patients with *secondary progressive* multiple sclerosis.

Treatment is initiated with **first-line drugs**: Interferon beta-1a (Avonex®, Rebif® and Plegridy®) and interferon β-1b (Betaferon® and Extavia®), the synthetic copolymer glatiramer acetate, dimethyl fumarate and teriflunomide.

**Interferon beta** is 166-amino acid glycoprotein produced by fibroblasts and some other cells in response to viral infections. Natural human beta-interferon is produced from human fibroblasts, but large-scale production requires the use of recombinant DNA technologies.

Two recombinant molecules have been produced from human beta-interferon by genetic engineering. Interferon beta-1a is produced from Chinese hamster ovary cells and therefore is glycosylated like the natural protein. Interferon β-1b is produced from strain of *Escherichia coli* and as such it differs from the natural sequence at position 17, which has been mutated, is one amino acid shorter than the natural protein, lacking the N-terminal methionine residue and also lacks the glycosylation at asparagine residue at position 80 that exists in the natural protein. These changes have been made in view of the stability of the molecule and do not affect its function. The two products have equal physical and chemical properties, and equal pharmacodynamic and pharmacokinetic characteristics.

In multiple sclerosis, beta-interferon inhibits the activation and proliferation of the autoreactive T-cells and their transmigration across the blood-brain barrier to the CNS, where they mediate myelin/oligodendrocyte damage. Interferon beta stimulates the production of anti-inflammatory cytokine interleukin 10 and inhibits the production of IFN-gamma, which enhances immune responses. Clinical improvement is observed after 2 to 12 months of treatment and the effect lasts for 6 months following discontinuation of IFNs.
Interferon $\beta$-1b (Betaferon®, Extavia®) is the first interferon approved for the treatment of multiple sclerosis in the USA (1993) and EU (1995). Administered subcutaneously every other day at a dose of 250 $\mu$g, equal to 8 million IU.

Interferon $\beta$-1a is available in two forms.

The intramuscular injection (Avonex®) is administered once a week at a dose of 6 million IU (30 $\mu$g).

The subcutaneous injection (Rebif®) is administered 3 times a week at a dose of 12 million IU (44 $\mu$g).

Published clinical trials with each one of the three drugs have confirmed undoubtedly their clinical efficacy. Interferons reduce the rate and severity of relapses as corroborated by MRI findings. Their clinical efficacy in patients with relapsing-remitting MS was first confirmed with interferon $\beta$-1b in 1993. The medication reduces the annual relapse rate by 30%, with 31% of patients remaining relapse-free during the first 2 years of treatment; the time to first relapse is doubled, the severity of relapses and the number of moderate and severe type of relapses is reduced by 50%. Interferon also extends the time to disability progression and reduces the number of hospitalizations and number of patients in need of corticosteroid treatment. MRI findings show 75% annual reduction of new lesions. Other IFNs have shown consistent results.

Interferon $\beta$-1b reduces the rate and severity of superimposed relapses in patients with secondary progressive multiple sclerosis, extends the time to disability progression by approximately 12 months for a period of 2 years and reduces the number of new lesions on MRI.

Pegylated interferon $\beta$-1a for subcutaneous administration (Plegridy®) was approved in 2014 by FDA and EMA for the treatment of patients with multiple sclerosis. The recommended dose is 125 $\mu$g s.c. every 2 weeks. The treatment starts with 63 $\mu$g at dose 1, increasing to 94 $\mu$g at dose 2, and the full dose of 125 micrograms is reached with the third administration. The prolonged absorption of the drug results in longer half-life, higher stability and activity and extended dosing intervals. The reduction in clearance rate and immunogenicity does not interfere with the drug safety and tolerability.

Clinical trials have shown reduction of the annual relapse rate by 36%, and reduction of the risk of sustained disability progression by up to 38%. The number of new or newly enlarged $T_2$ lesions is reduced by up to 67%), the number of $T_1$ hypointense lesions by up to 53% and the number of Gd-enhancing lesions – by up to 86%.

The side effects of beta-interferon treatment include local skin reactions, flu-like symptoms and rarely fatigue, worsening of depression, asthenia, headache, hepatic transaminase increase, cytopenia and thyroid disorders. The adverse drug reactions associated with subcutaneous administration of pegylated interferon $\beta$-1a do not differ from those with the conventional dosage
forms. Flu-like symptoms such as hyperpyrexia, chills and myalgia are mostly manifested in the first 24 hours after the first dose and resolve within 6-7 days. They are more manifested with interferon β-1b due to more frequent dosing. The use of nonsteroid anti-inflammatory drugs (ibuprofen, aspirin) at initiation of interferon therapy helps reduce flu-like effects. Local skin reactions at the site of injection can be reduced by training patients or nurses injecting the drug on proper injection techniques and use of rotation charts to alternate injection sites.

The biological activity of interferon β-1b is much more pronounced and stable compared with interferon β-1a intramuscular injection once a week. Interferon β-1b has the highest biological activity followed by interferon β-1a subcutaneous injection and β-1a intramuscular injection with the lowest biological activity due to its smaller weekly dosage. The biological activity of pegylated interferon β-1a is significantly higher and more stable over time compared with the conventional dosage form.

The clinical efficacy of the three β-interferon types is also different due to differences in dosing. Less frequent dosing is more convenient and associated with less side effects but the clinical efficacy is lower. The highest reductions in the annual relapse rate and number of severe relapses and hospitalizations and the longest time to first relapse have been observed in patients treated with interferon β-1b. The clinical efficacy of pegylated interferon β-1a is higher than that of interferon β-1a intramuscular injection and similar to that of interferon β-1b and interferon β-1a subcutaneous injection.

The four beta-interferon agents are not interchangeable and in patients with aggressive disease, the use of interferon β-1b or pegylated interferon β-1a is preferred.

Neutralizing antibodies (NAbs) will be developed in 10-35% of patients after 1-year treatment with beta-interferon which reduces clinical efficacy. NAbs are mostly seen with interferon β-1b due to more frequent dosing. Immunogenicity is highest in Betaferon and Extavia (35%), lower in Rebib (15% to 23%), and weakest in Avonex® (2% to 5%). Only 1-3% of patients receiving pegylated interferon β-1a will develop persisting neutralizing antibodies. NAbs may disappear over time and then the clinical efficacy of the drug will be recovered.

When testing for neutralizing antibodies is impossible, the changes in therapy are based on clinical parameters. Availability of antibodies against one of the beta interferon types means that switching to another interferon is worthless because of cross-reaction among NAbs and IFNbeta-1a and IFNbeta-1b. However, such cross-reactivity is not seen with other drugs, which makes the switching to another therapy possible, in case of lack of clinical efficacy of IFN treatment.

Glatiramer acetate (copolymer-I) is administered subcutaneously, once daily at a dose of 20 mg/ml. It is a molecule composed of synthetic polypeptides of four amino acids: L-glutamine, L-
lysine, L-alanine and L-tyrosine in a fixed ratio. Approved in 1996 in the USA for the treatment of patients with relapsing-remitting multiple sclerosis.

The mode of action of GA is associated with induction of specific suppressor cells of the T helper 2 (Th2) type which migrate to the brain and suppress the activation of myelin basic protein by the reactive T helper (Th1) type cells which produce pro-inflammatory cytokines and induces production of Th2 type cells that produce anti-inflammatory cytokines. Furthermore, the GA-acetate reactive T cells release brain-derived neurotrophic factor (BDNF), which accelerates the recovery of damaged axons and neurons and promotes remyelination. The main effect of the drug is suppression of inflammation and autoimmune responses in multiple sclerosis. GA reduces the rate of clinical relapses and the number of new or newly enlarged lesions on MRI by 30%. There is no data about its efficacy in secondary progressive form of the disease.

The first **generic glatiramer acetate** 20 mg was approved by FDA in 2015. **Glatiramer acetate 40 mg/ml** for subcutaneous use 3 times a week was approved by FDA in 2015 for the treatment of relapsing-remitting multiple sclerosis. It has the same clinical efficacy as the conventional dose of 20 mg/ml daily.

*The side effects are mainly local: pain, erythema, pruritus, inflammation and hardening of the tissues, which resolve spontaneously. Rarely causes fatigue, depression, asthenia, headache, allergic and post-injection systemic reactions. GA does not cause flu-like symptoms.*

GA induces development of **neutralizing antibodies** reaching peak titters 3 to 6 months after initiation of treatment, after which the levels decrease. The presence of NAbs does not reduce the therapeutic efficacy of glatiramer acetate.

**Dimethyl fumarate (Tecfidera®)** is a fumaric acid derivative with anti-inflammatory, cytoprotective and immunomodulating properties. The drug was approved in 2013 by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. For oral use in patients aged between 18 and 65 years. The starting dose is 120 mg twice a day. After 7 days, the dose is increased to the recommended dose of 240 mg twice a day.

Dimethyl fumarate activates the transcriptional pathway of the nuclear factor (Nrf2), which leads to activation of the synthesis of anti-inflammatory interleukins, reduction of proinflammatory cytokines, stimulation of the expression of antioxidant and detoxification enzymes and reduction of leukocyte adhesion molecules.

Clinical studies have shown reduction in the annual relapse rate by 44-53%, and of the risk for sustained progression of disability by up to 38%. The risk for Gd+ lesions is reduced by 74% to 90%, and the risk of developing new or newly enlarging $T_2$ hyperintense lesions is reduced by 71% to 85%.
The most common adverse reactions are flushing, diarrhoea, nausea, abdominal pain, which occur early in the course of treatment (in the first month), but may continue to occur intermittently throughout the treatment period. The risk of lymphopenia cannot be ruled out and 4 cases of PML, associated with prolonged lymphopenia, have been reported. Temporary dose reduction to 120 mg twice a day may reduce the adverse reactions. Within 1 month, the recommended dose of 240 mg twice a day should be resumed.

The drug is contraindicated in patients with persisting severe lymphopenia and severe renal and hepatic impairment.

There is no data on the development of anti-drug neutralizing antibodies.

Teriflunomide (Aubagio®) is a purine analogue with immunosuppressive properties. The recommended dose is 14 mg once daily orally in patients aged 18-65 years. Approved for the treatment of relapsing-remitting multiple sclerosis by FDA and EMA in 2012 and 2013, respectively.

Teriflunomide is an active metabolite of leflunomide, which is used for the treatment of rheumatoid arthritis. It selectively and reversibly inhibits the mitochondrial enzyme dihydroorotase dehydrogenase, engaged in the de novo synthesis of pyrimidines, required for the proliferation of dividing B- and T-lymphocytes. Consequently, teriflunomide inhibits the abnormal proliferation and activation of pathogenic T- and B-cells. Through this cytostatic effect, teriflunomide inhibits the immune responses associated with disease activity. Resting lymphocytes are not damaged, so they can still divide and proliferate at a low level, using available pyrimidines. As a result, the previously acquired cell immunity is preserved and the risk of infectious diseases does not increase.

Clinical studies in patients with relapsing-remitting multiple sclerosis have shown a 30% reduction in the annual relapse rate, 60% reduction in the number of active and new lesions on MRI, and 80% reduction of gadolinium-enhanced lesions.

The side effects include upper respiratory tract infections, headache, diarrhoea, nausea, alopecia or hair thinning, high blood pressure or alanine aminotransferase (ALT) increase. Isolated cases of toxic hepatic necrosis, pancytopenia and teratogenic effects have been reported.

The clinical efficacy of the first-line therapy glatiramer acetate 20 and 40 mg/ml and teriflunomide is similar to that of beta interferons. The clinical efficacy of dimethyl fumarate is higher than that of the other first-line therapy drugs.

Despite Avonex’s lower efficacy compared to other beta interferons, given the fewer side effects, more convenient administration as well as less frequent antibodies production, Avonex and Plegridy, may be used in young active patients with shorter duration and lower activity of the disease.

In cases of unsatisfactory clinical efficacy or increased disease activity, switching to betaferon (Extavia®), Rebif®, glatiramer acetate, teriflunomide or dimethyl fumarate is recommended. However, it has to be considered that betaferon (Extavia®) is associated with frequent development
of antibodies and the highest incidence of adverse reactions. In the presence of clinical evidence of development of antibodies to beta interferons switching to glatiramer acetate, teriflunomide or dimethyl fumarate is advised. Patients with unsatisfactory clinical response to a certain drug might respond well to another one. When all first-line treatment options have been used-up, second-line therapies should be prescribed.

Switching from intravenous to oral therapy for patient's convenience only, without a medical reason (unsatisfactory efficacy or intolerance), is not recommended.

**Treatment of different forms of multiple sclerosis** has its specifics.

Patients with **clinically isolated symptoms**, who do not fulfil the criteria for multiple sclerosis, are at a high risk of a second relapse, after which the diagnosis will be definitive. Treatment of such patients delays onset of further relapses and definitive diagnosis. In patients with very high MRI activity manifested in multiple lesions (10-20 lesions) and multiple contrast-enhancing lesions, initiation of disease-modifying therapy is recommended. In patients with moderate MRI findings, suggesting lower disease activity, further clinical relapse may be awaited to make a final diagnosis and initiate treatment.

<table>
<thead>
<tr>
<th>In the beginning of the disease, in patients with clinically isolated symptoms:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• First-line disease modifying drugs are recommended</td>
</tr>
</tbody>
</table>

**Treatment of relapsing-remitting form** of the disease with first-line disease modifying drugs should be initiated as soon as diagnosis is made, to prevent new lesions. This is of particular importance in patients with high clinical and MRI activity of the disease. Early treatment can change the natural course of the disease by reducing the rate and severity of relapses, delaying the disease progression, disability and incapacity for work (by an average of 18 months), improving patients’ quality of life, and prolonging their life.

- The neurologist should determine the form of disease and decide on the initiation and type of treatment during a period outside relapse.
- The treatment should continue for 1 year, thereafter the neurologist should assess the treatment efficacy (Appendix 5).
- In the presence of evidence of decreased clinical efficacy, assessed by the criteria for treatment efficacy, a change in therapy should be considered. It is recommended that clinical evidence is corroborated by testing for neutralizing antibodies.
- Whenever possible, testing for neutralizing antibodies with predictive value should be performed in all patients 18 months after initiation of interferon therapy.
Treatment of newly diagnosed relapsing-remitting multiple sclerosis:

- **First-line treatment** – Beta interferons (including pegylated beta interferon), glatiramer acetate, teriflunomide or dimethyl fumarate;
- **Second-line treatment** – S1P receptor modulators, the selective immunosuppressor cladribine or monoclonal antibodies;
- Hygiene and dietary regime;
- Symptomatic treatment.

The treatment of multiple sclerosis in children (under 16 years of age) still presents a great challenge. Corticosteroid therapy can be used for relapse management. The use of disease modifying therapies in children is not allowed. No clinical trials have been conducted with pediatric MS medications, although results from small scale studies have shown clinical efficacy and safety similar to that in adult patients.

Based on limited published data, it might be assumed that the safety profile of betaferon (Extavia®), Avonex® and glatiramer acetate are given at doses recommended for adults in adolescents between 12 and 16 years of age, and Rebif® given to children and adolescents (12 to 17 years old) would be similar to that in adult patients. Treatment of pediatric patients follows a titration schedule based on the patient’s body weight and should be under the physician’s responsibility. Due to the high relapse rate in adolescence leading to earlier disability, the use of disease modifying therapies can be recommended. The benefits of an early treatment, immediately after a definitive diagnosis had been made, are undeniable.

### Criteria for beta-interferon and glatiramer acetate therapy in patients with relapsing-remitting multiple sclerosis

**I. Inclusion criteria:**

1. Multiple sclerosis diagnosed according to [2010 revised diagnostic criteria](#)
2. Age > 16 years (>18 years for glatiramer acetate and pegylated beta-interferon)
3. Disability score of up to 4.0 (Kurtzke Expanded Disability Status Scale [EDSS])

**II. Exclusion criteria**

1. Concomitant chronic conditions/diseases that shorten life expectancy (alcohol abuse, dementia, psychotic disorders, active malignancies)
2. Patients with severe depression and suicide attempts during treatment (beta interferons only)
3. Pregnancy (except for glatiramer acetate at physician's discretion)

**III. Treatment is not administered or if initiated, should be discontinued in cases of:**
1. Pregnancy of female patients (except for glatiramer acetate at physician's discretion)
2. Serious adverse effects of treatment
3. High patient non-compliance
4. Lack of clinical efficacy of the therapy (2 or more relapses in a year)
5. Patients treated with beta-interferons without clinical effect and/or in the presence of neutralizing antibodies, might be switched to other first- or second-line therapies, depending on the disease activity
6. First-line treatment failure; Switching to second-line therapies for such patients may be considered
7. Disability progression to EDDS = 5
8. Reaching the age of 59, and absence of disease activity in the last 2 years

<table>
<thead>
<tr>
<th>Criteria for dimethyl fumarate therapy in patients with relapsing-remitting multiple sclerosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I. Inclusion criteria:</strong></td>
</tr>
<tr>
<td>1. Multiple sclerosis diagnosed according to <strong>2010 revised diagnostic criteria</strong></td>
</tr>
<tr>
<td>2. Ages of 18 to over 60</td>
</tr>
<tr>
<td>3. EDSS score of up to 4.0</td>
</tr>
<tr>
<td><strong>II. Exclusion criteria:</strong></td>
</tr>
<tr>
<td>1. Pregnancy or planning for pregnancy</td>
</tr>
<tr>
<td>2. Patients with immunodeficiency syndrome or receiving immunosuppressive therapy</td>
</tr>
<tr>
<td>3. Active acute or chronic infections (hepatitis, tuberculosis)</td>
</tr>
<tr>
<td>4. Neoplasms, except cutaneous cell skin carcinoma</td>
</tr>
<tr>
<td>5. Severe hepatic impairment</td>
</tr>
<tr>
<td><strong>III. Treatment should not be administered, or discontinued (if initiated) in cases of:</strong></td>
</tr>
<tr>
<td>1. Pregnancy</td>
</tr>
<tr>
<td>2. Serious adverse drug reactions</td>
</tr>
<tr>
<td>3. High level of non-adherence to the therapy</td>
</tr>
<tr>
<td>4. Lack of clinical efficacy of the therapy (2 or more relapses per year)</td>
</tr>
<tr>
<td>5. Failure of first-line treatment; Switching to second-line therapies might be considered depending on the disease activity</td>
</tr>
<tr>
<td>6. Disability progression to EDDS = 5</td>
</tr>
<tr>
<td>7. Reaching the age of 59, and absence of disease activity during the last 2 years</td>
</tr>
</tbody>
</table>
Laboratory tests and follow-up evaluations required during dimethyl fumarate therapy

**I. Prior to the initiation of treatment:**
1. A recent complete blood count (within 1 month), serum aminotransferases and bilirubin, blood urea nitrogen and creatinine

**II. During treatment:**
1. Assessment of renal function (creatinine, blood urea nitrogen, and urinalysis) and serum aminotransferases at 3 and 6 months of treatment, every 6 to 12 months thereafter, and as clinically indicated
2. Regular assessment every 6 months of complete blood count; treatment discontinuation in lymphocyte counts < 0.2 x 10⁹/l until recovery
3. Patients should be instructed to inform the physician of any signs and symptoms of infection

Criteria for teriflunomide therapy in patients with relapsing-remitting multiple sclerosis

**I. Inclusion criteria:**
1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria;
2. Ages of 18 to over 60
3. EDSS score of up to 4.0

**II. Exclusion criteria:**
1. Severe immunodeficiency
2. Severe active infection until recovery
3. Significant bone marrow disorder or significant anemia, leukopenia, neutropenia or thrombocytopenia
4. Severe hepatic impairment
5. Dialysis
6. Severe hypoproteinemia
7. Pregnancy or lactation

**III. Treatment is not administered or if initiated should be discontinued in cases of:**
1. Pregnancy. Accelerated elimination procedure is recommended to reduce plasma concentrations below 0.02 mg/L
2. Serious adverse drug reactions
3. High level of non-adherence to the therapy
4. Lack of clinical efficacy of the therapy (2 or more relapses per year)
5. In case of first-line treatment failure, switching to other therapies of first or second-line might be considered, depending on the disease activity. Over a period equal to 5 half-lives (3.5 months), starting another therapy leads to an additive effect on the immune system and requires increased caution.

6. Disability progression to EDDS = 5

7. Reaching the age of 59, and absence of disease activity during the last 2 years

**Laboratory tests and follow-up evaluations required during teriflunomide therapy**

**I. Prior to treatment initiation:**
1. A recent complete blood count (within 1 month) (including differential WBC count and platelet count), alanine aminotransferase (ALT/SGPT) levels and blood pressure

**II. During treatment:**
1. Regular assessment of liver enzymes ALT (SGPT) – every two weeks during the first 6 months of treatment, and every 8 weeks thereafter, or as clinically indicated. For elevations 3 times the upper limit of normal, discontinuation of therapy should be considered
2. Complete blood cell counts should be performed based on signs and symptoms (e.g. infections) during treatment
3. Monitoring and management of the hypertension

**Strict hygiene and diet regimen is recommended in patients with multiple sclerosis:**
- Sufficient rest and avoidance of physical and mental exertion
- Protection against over-cooling and overheating
- Protection against common colds
- Reduction of dietary intake of salt and animal fats in favour of foods rich in polyunsaturated fatty acids (linoleic acid) and Vitamin D, and cessation of tobacco smoking
- Medical exercise therapy.

**The drugs for second-line treatment** in patients with relapsing-remitting disease include the S1P-receptor modulator fingolimod, the monoclonal antibodies natalizumab, and alemtuzumab or the selective immunosuppressant cladribine. Currently, these drugs are the most efficient agents for the treatment of relapsing-remitting multiple sclerosis. They are used when first-line therapies fail or are contraindicated. Second-line treatment drugs are contraindicated during pregnancy and during planned conception.
S1P receptor modulator fingolimod (Gilenya®) has been found to have immune-modulating properties. The recommended dose in patients aged 18-65 is one 0.5 mg capsule taken orally once daily. It has been approved for the treatment of multiple sclerosis in 2010 (for the USA), and in 2011 (for the EC).

Gilenya® is indicated as second line modifying therapy in patients with highly active disease despite a full one-year course of treatment with at least one disease modifying therapy. Unresponsiveness to therapy is defined by at least 2 relapses in one year or increased rate and severity of relapses as compared to the previous year. Patients with a significant increase in T2 lesion load as compared to a previous recent MRI might also be considered for treatment. Patients should have at least 9 hyperintense T2 lesions on brain MRI.

Fingolimod is a structural analogue of sphingosine 1-phosphate (S1P), a modulator of sphingosine 1-phosphate receptors which play a role in the processes of inflammation and regeneration. S1P receptors are expressed in lymphoid tissues, and S1P5 receptors – in the white matter of the central nervous system.

The drug converts endogenous sphingosine to a phosphate form, which binds to sphingosine 1-phosphate receptors 1(S1P1) located on the lymphocytes. This promotes receptor internalisation and deprives lymphocytes of their capability to recognise the signal for egression from lymphoid tissues. The capacity of lymphocytes to egress from lymph nodes and thymus gland and their migration to the CNS is blocked. As a result, T- and particularly B-lymphocyte counts in peripheral blood decrease (by 25% from baseline). The functions of lymphocytes, which remain in secondary lymphoid organs and peripheral blood, are not affected. The drug crosses the blood-brain barrier and stimulates central nervous system receptors leading to inhibition of neurodegenerative and promotion of regenerative processes. It induces thymocyte apoptosis, inhibits brain capillary permeability mediated by the vascular endothelial growth factor (VEGF), stabilises the blood-brain barrier integrity, shifts cytokine production from Th1 (pro-inflammatory) to Th2 (anti-inflammatory) cytokines and reduces macrophage transmigration to brain parenchyma.

Fingolimod reduces the annual relapse rate by 50% and the number of active lesions on MRI by 60%. Fingolimod delays the progression of sustained disability by 37%.

Serious adverse reactions are associated with infections, macular edema and AV block. Less serious adverse reactions include flu-like symptoms, headache, diarrhoea, depression, back pain, cough, hypertension, lymphopenia, leukopenia, and increased serum transaminases.

Contraindicated in patients with immunodeficiency syndrome receiving immunosuppressive therapy, active infection (hepatitis, tuberculosis) cardiac rhythm, and conduction disturbances, AV block, sick-sinus syndrome, sinoatrial block, symptomatic bradycardia, recurrent syncope, prolonged QT-interval, patients receiving anti-arrhythmic and heart-rate reducing drugs, patients with
uncontrolled hypertension, chronic obstructive pulmonary disease, pulmonary fibrosis, neoplasm, hepatic impairment, and pregnancy.

Criteria for the treatment of multiple sclerosis with sphingosine 1-phosphate receptor modulators in patients with relapsing-remitting disease

I. Inclusion criteria:
1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria
2. Ages of 18 to over 60
3. EDSS score of up to 4.0
4. Aggressive disease course with increased relapse rate (at least 2 relapses in the previous year) – despite treatment with first-line drugs
5. Significant increase in T2 lesions compared to the latest MRI scan during the last 12 months
6. JCV-positive patients with previous 2-year treatment with natalizumab.

II. Exclusion criteria:
1. Patients with immunodeficiency syndrome or receiving immunosuppressive therapy
2. Active acute of chronic infections (hepatitis, tuberculosis)
3. Neoplasms, except cutaneous cell skin carcinoma
4. Severe hepatic impairment
5. Patients with an AV block II degree Mobitz 2 type or higher, sick sinus syndrome or sinoatrial block, history of symptomatic bradycardia or recurrent syncope, significant QT prolongation (> 470 ms in women and > 450 ms in men)
6. Treatment with class Ia antiarrhythmic agents (quinidine, disopyramide) or class III (amiodarone, sotalol), beta-blockers, heart rate-lowering calcium channel blockers (verapamil, diltiazem or ivabradine) or other substances that can lower heart rate (digoxin, anticholinesterase agents or pilocarpine)
7. Pregnancy

III. Treatment is not administered or if initiated should be discontinued in cases of:
1. Pregnancy
2. Serious adverse drug reactions
3. High level of non-adherence to the therapy
4. Lack of clinical efficacy of the therapy (2 or more relapses per 1 year)
5. Patients can switch to alemtuzumab, natalizumab or cladribine after a 1-month wash-out period
6. Disability progression to EDDS = 5
7. Reaching the age of 59, and absence of disease activity during the last 2 years
Laboratory tests and follow-up evaluations required during fingolimod therapy:

I. Prior to treatment initiation:
1. A recent complete blood count (within 1 month) and transaminase and bilirubin levels
2. Testing for antibodies to varicella zoster virus (VZV). Vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment
3. Ophthalmological evaluation

II. At treatment initiation:
1. ECG, consultation with an internist, and blood pressure measurement before and 6 hours after the first dose of fingolimod
2. Monitoring for a period of 6 hours for symptoms of bradycardia with hourly heart rate and blood pressure measurement. Continuous (real time) ECG monitoring is recommended

III. During treatment:
1. Ophthalmological assessment is recommended at 3-4 months after treatment initiation
2. Liver transaminases should be monitored at 1, 3, 6, 9, and 12 months after initiation of therapy, and every 6 months thereafter
3. Periodic follow-up every 6 months of complete blood count and discontinuation of treatment when the lymphocyte count drops below 0.2x10⁹/l, until recovery
4. Patients must report visual disturbances or signs and symptoms of infection at any time while on therapy
5. If treatment is interrupted for more than 2 weeks, patients should be monitored for 6 hours upon the resumption of treatment.

Monoclonal antibodies have caused a revolution in the treatment of autoimmune diseases. Recent advances in monoclonal antibody technology have enabled the development of quite specifically targeted immunotherapies. The problem is that such specific therapies may not be appropriate for diseases without fully elucidated underlying immunopathology, because of the risk of unforeseeable and undesirable effects.

Natalizumab (Tysabri®) is the first humanised monoclonal antibody, approved by FDA for the treatment of relapsing-remitting multiple sclerosis. Administered at a dose of 300 mg as a 1-hour intravenous infusion once monthly (every 4 weeks). A second-line therapy in younger patients with early and active disease course with prevailing inflammatory changes. Given the risk of severe side effects, natalizumab should be used as monotherapy only in patients with aggressive relapsing-remitting disease who are preferably negative for JC virus (JCV) antibodies and do not respond to
first-line therapy. Should not be combined with other disease modifying drugs because of the risk of severe complications. The half-life of natalizumab is 11 days.

Natalizumab is a recombinant anti-α4-integrin antibody, targeting the α4-subunit (CD49d) of α4-β1 and α 4-β7 (VLA-4) of integrin receptors on the surface of activated T cells. Natalizumab binds the integrin T-cell specific receptor antigenVLA-4 (Very Late Appearing Antigen-4), which mediates binding to brain endothelium adhesion molecule-1 (VCAM-1) and promotes transmigration of circulating T cells into the CNS. In this way, it blocks the interaction of lymphocyte integrin receptors with VCAM-1 receptors on the vascular endothelial membrane. Partially inhibits leukocyte activation, proliferation and migration to the sites of inflammation.

Natalizumab reduces the relapse rate by approximately 60% and MRI lesions by 90%. It also reduces the number of new MRI lesions and their conversion to “black holes” associated with axonal loss. Improves inflammatory demyelination-mediated visual disorders. Reduces the risk of disability progression by 25-40%. Natalizumab’s efficacy increases during the second year of treatment.

The biological markers of natalizumab activity are not studied yet, but drug concentrations, easily measured with ELISA, are objective markers of its bioavailability.

Neutralizing antibodies to natalizumab develop in about 10% of patients as soon as after the third infusion. Although it is a humanised monoclonal antibody, as small part of it, which is produced from mice, is susceptible to antibodies. In 6% of patients, neutralizing antibodies persisting over time reduce the clinical efficacy of the drug and increase its allergic side effects. In some patients, NABS disappear within about 2 years.

The adverse reactions are associated with fatigue, headache, depression, joint pain, urinary and pulmonary (bronchopneumonia) infections, and abdominal discomfort. Less than 1% of patients experience serious hypersensitivity reactions. Because of reported cases of hepatotoxicity, the medication is contraindicated in patients with evidence for hepatic disease.

Progressive multifocal leukoencephalopathy (PML) is the severest treatment complication. It is a result of disturbance of the T lymphocyte-mediated immunity (dramatic decrease of T cells) and premature development of pre-B cells in the bone marrow. Natalizumab increases the level of circulating B cells which carry the JC polyomavirus which causes PML. The number of CD4 cells, which play an important role in the control of the infection, is also reduced. However, the treatment benefits exceed the risk of potential life-threatening PML.

The risk of PML development is determined by screening for the presence of anti-JC virus antibodies, prior to treatment initiation. Repeat testing on a yearly basis is recommended, since every year 2% of the population are likely to experience spontaneous seroconversion of the antigen status. The risk of development of leukoencephalopathy is highest during the third year of treatment. In JCV
antibody-positive patients who have received one or two years of treatment with natalizumab a change of therapy should be considered.

If PML occurs, the immune effector response should be promptly restored by restoring the capability of leukocytes to migrate across the blood-brain barrier suppressed by natalizumab. This is achieved by plasma exchange, which reduces α4 integrin saturation.

Criteria for treatment of multiple sclerosis with the monoclonal antibody natalizumab in patient with relapsing-remitting disease

I. Inclusion criteria:
1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria
2. Age of 18 to over 60
3. EDSS score of up to 4.0
4. Aggressive disease course with increased relapse rate (at least 2 relapses during the preceding year), despite treatment with first-line drugs
5. Significant increase in T2 lesions compared to the latest MRI scan during the last 12 months

II. Exclusion criteria:
1. Severe comorbidities – cardiac diseases, pulmonary diseases, renal or hepatic disorders and infections
2. Anti-JCV antibody positive patients during the second year of treatment
3. Pregnancy or planning for pregnancy during the next three years

III. Treatment is not administered or if initiated should be discontinued in cases of:
1. Pregnancy
2. Serious adverse drug reactions:
   • In case of onset of new neurological symptoms, the assumed causes are PML or another opportunistic infection until the condition is clarified
   • MRI scan and lumbar puncture for JCV testing should be considered
   • In case of negative test results, it is assumed that the new symptoms are a result from disease attack and appropriate treatment should be initiated
   • If symptoms resolve following treatment, dosing of natalizumab may resume.
3. High level of non-adherence to the therapy
4. Lack of clinical efficacy of the therapy (2 or more relapses per 1 year)
5. Patients may switch to fingolimod, alemtuzumab or cladribine after a 2-month wash-out period
6. Disability progression to EDDS = 5
7. Reaching the age 59 years and absence of disease activity during the last 2 years
8. After a 2-year treatment, due to increased risk of developing PML, patients may switch to treatment with fingolimod or alemtuzumab after a 2-month wash-out period
9. PML has been reported following discontinuation of natalizumab. Monitoring is recommended especially in patients who have switched to other therapies with potential risk of PML development

**Laboratory tests and follow-up evaluations required during natalizumab therapy**

**I. Prior to treatment initiation:**
1. MRI
2. Testing for anti-JCV antibodies

**II. During treatment:**
1. Annual testing for anti-JCV antibodies
2. Monthly monitoring for changes in neurological status
3. Evaluation of ALAT, ASAT and bilirubin every 6 months
4. MRI screening every 6 months for JC-positive patients

**Alemtuzumab** (Lemtrada®) is a humanised monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia. In 2013, this medicinal product was approved by FDA for first-line treatment of relapsing-remitting multiple sclerosis. In 2014, FDA approved its use only as second-line treatment in patients with aggressive disease course who have not responded to first-line therapy. The drug is not efficient in secondary progressive multiple sclerosis.

The drug is administered once a year at a dose of 12 mg/day by 4-hour intravenous infusion on 5 consecutive days (60 mg total dose), followed by three consecutive infusions (36 mg total dose) given 12 months after the initial treatment cycle. The benefits and risks of more than 2 treatment cycles have not been fully established, but the safety profile does not appear to change with additional courses.

Alemtuzumab binds to CD52, a cell surface glycoprotein receptor antigen presents on lymphocytes (T and B cells) and on natural killer cells, monocytes, and macrophages. It causes apoptosis and depletion of lymphocytes with CD52 receptors via antibody-mediated cell toxicity. Lymphocytes repopulate over time with B-cell recovery usually completed within 6 months, while T-cell repopulation takes longer. CD8+ T cell counts rise to normal within about 30 months, but CD4+ T cell counts – not earlier than 5 years post-treatment. Due to B cell activation and transient elevation of cytokine levels after treatment initiation, a temporary neurological decline might be observed. There is no evidence that the drug affects the immunological memory for antibodies to
common viruses and vaccines. The ability of generation of humoral immune responses against new antigens is also preserved.

Clinical trials in patients with relapsing-remitting multiple sclerosis have shown reduction of the annual relapse rate by 55% versus subcutaneous interferon β-1a, and reduction in contrast-enhancing T₂ lesions and brain atrophy on MRI, but no significant effect on disability progression. In patients with unsatisfactory outcome from previous IFN beta treatment, alemtuzumab reduced the relapse rate and risk of disability progression by 40%. In patients with early-phase disease improvement of disability and brain volume increase have been observed, probably due to the release of neurotrophic factors from immune cells recovering after treatment.

*Inhibitory antibodies* have been found in 85% of patients, but are not associated with decrease in efficiency and adverse reactions.

*Adverse reactions* include infusion reactions such as chills, rash, headache, nausea and vomiting; upper respiratory tract and urinary tract infections, lymphopenia, leukopenia, flushing, nausea, fatigue, as well as transient neurological decline (for several hours) due to the release of cytokines. For their control, premedication with corticosteroids (methylprednisolone 1,000 mg) is given for the first 3 days of each treatment cycle.

*Secondary autoimmune complications*, occurring within 5 years after treatment but reaching a peak in the second-year post-treatment, are a major issue.

*Autoimmune hyperthyroidism* (Graves’s disease) develops in 30% of patients as a result of development of antibodies to thyrotropin receptors. Autoimmune hyperthyroidism occurs within 48 months following first alemtuzumab exposure. Most complications are mild to moderate in severity and serious events occur in less than 1% of patients.

*Idiopathic immune thrombocytopenic purpura* occurs in 2% of patients between 14 and 36 months after first exposure.

*Nephropathies*, including anti-glomerular basement membrane disease, have been observed in 0.3% of patients within 39 months after the last dose.

Prophylaxis with an oral anti-herpes agent (acyclovir 200 mg BID) should be initiated in all patients starting on the first day of each treatment cycle and continuing for at least 1 month.

---

**Criteria for treatment of multiple sclerosis with alemtuzumab in patients with relapsing-remitting disease**

1. **Inclusion criteria:**
   1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria
   2. Age from 18 to over 60 years
   3. EDSS score of up to 4.0
4. Aggressive disease course with increased relapse rate (at least 2 relapses during the preceding year), despite treatment with first-line drugs

5. Significant increase in T2 lesions compared to the latest MRI scan during the last 12 months

II. Exclusion criteria:
1. Severe comorbidities – cardiac, pulmonary, renal and hepatic disorders and infections
2. Human immunodeficiency virus (HIV) infection
3. Pregnancy and breast feeding

III. Treatment is not administered or if initiated should be discontinued in:
1. Pregnancy of female patients
2. Serious adverse drug reactions
3. High level of non-adherence to the therapy
4. Lack of clinical efficacy of the therapy (2 or more relapses per 1 year)
5. The patient can switch to treatment with sphingosine 1-phosphate receptor modulators, natalizumab or cladribine
6. Disability progression to EDDS = 5
7. Reaching the age 59 years and absence of disease activity during the last 2 years

---

Laboratory tests and follow-up evaluations required during alemtuzumab therapy

I. Prior to treatment initiation:
1. Complete blood count with differential
2. Serum creatinine levels
3. Urinalysis with microscopy
4. Thyroid function evaluation – thyroid stimulating hormone (TSH) levels
5. Screening for active and latent tuberculosis with T-spot test. In patients with active infection initiation of treatment is delayed until the infection is fully controlled
6. Testing for anti-VZV antibodies in patients without a history of chickenpox or without varicella zoster virus (VZV) vaccine. VZV vaccination of antibody-negative patients should be considered prior to treatment initiation
7. Screening for hepatitis B and C viruses
8. Treatment should not be initiated in case of any active infection

II. During treatment and for 48 months following the last treatment course:
1. Complete blood count with differential (monthly)
2. Serum creatinine levels (monthly)
3. Urinalysis with microscopy (monthly)
4. Thyroid function evaluation – thyroid stimulating hormone (TSH) levels – every 3 months
**Cladribine (Mavenclad)** is a selective immunosuppressor. The product was approved by EMA in August 2017 for the treatment of adult patients with highly active relapsing multiple sclerosis.

Orally administered at a cumulative dose of 3.5 mg/kg body weight for 2 years, administered as 1 treatment cycle of 1.75 mg/kg per year. Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective treatment year. Each treatment week consists of 4 or 5 days on which a patient receives 10 mg or 20 mg (one or two tablets) as a single daily dose, depending on body weight. Following completion of the 2 treatment cycles, no further cladribine treatment is required in years 3 and 4. Re-initiation of therapy after year 4 has not been studied.

Cladribine is a nucleoside analogue of deoxyadenosine. The mechanism by which cladribine exerts its therapeutic effects in MS is not fully elucidated, however its predominant effect on B and T lymphocytes is thought to interrupt the cascade of immune events central to MS. Cells of the innate immune system are less affected than cells of the adaptive immune system. Treatment with cladribine leads to rapid reductions in circulating CD4+ and CD8+ T cells. CD8+ T cells have a less pronounced decrease and a faster recovery than CD4+ T cells, resulting in a temporarily decreased CD4 to CD8 ratio. Cladribine reduces CD19+ B cells and CD16+/CD56+ natural killer cells, which also recover faster than CD4+ T cells.

Cladribine reduces the annual relapse rate by 58% and the mean number of T1 Gd+ lesions on MRI by 86%. The reduction of the risk of disability progression with cladribine compared to placebo is 47%. In patients with highly active disease, cladribine reduces the annual relapse rate by 66-68%, and the risk of disability progression by 82%.

The strength of its efficacy for reducing relapse rate and delay of disability progression is sustained during years 3 and 4 without need for further treatment.

*Adverse drug reactions* of highest clinical relevance are lymphopenia and herpes zoster. Transient grade 3 or 4 lymphopenia has been seen in up to 25% of patients mainly 2 months after the first cladribine dose in each treatment year. Transient grade 4 lymphopenia has been seen in less than 1% of patients. Most patients recover to either normal lymphocyte counts or grade 1 lymphopenia within 9 months.

*This drug is contraindicated* in: infection with human immunodeficiency virus (HIV), active chronic infection (tuberculosis or hepatitis), in immunocompromised patients, including patients currently receiving immunosuppressive or myelosuppressive therapy, active malignancy, moderate or severe renal impairment (creatinine clearance <60 mL/min), pregnancy and breast-feeding.
Criteria for treatment of multiple sclerosis with cladribine tablets in patients with relapsing-remitting disease

I. Inclusion criteria:
1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria
2. Age from 18 to over 60 years
3. EDSS score of up to 4.0
4. Aggressive disease course with increased relapse rate (at least 2 relapses during the preceding year) despite treatment with first-line drugs
5. Significant increase in T₂ lesions compared to the latest MRI scan during the last 12 months

II. Exclusion criteria:
1. Severe comorbidities – moderate or severe hepatic impairment (Child-Pugh score >6), moderate or severe renal impairment (creatinine clearance < 60 ml/min)
2. Human immunodeficiency virus (HIV) infection
3. Immunocompromised patients, including patients currently receiving immunosuppressive or myelosuppressive therapy
4. Active chronic infection (tuberculosis or hepatitis)
5. Pregnancy and breast feeding
6. Active malignancy

III. Treatment is not administered or if initiated should be discontinued in:
1. Pregnancy of a female patient
2. Serious adverse drug reactions
3. High level of non-adherence to the therapy
4. Lack of clinical efficacy of the therapy (2 or more relapses per 1 year)
5. The patient can switch to treatment with sphingosine 1-phosphate receptor modulators, natalizumab or alemtuzumab
6. Disability progression to EDSS = 5
7. Reaching the age 59 year and absence of disease activity during the last 2 years

Laboratory tests and follow-up evaluations required during therapy with cladribine tablets

I. Prior to treatment initiation (first cycle):
1. Complete blood count with differential: lymphocytes counts must be normal \( \geq 1,000 \text{ cells/mm}^3 \)
2. Serum transaminases, bilirubin, blood urea nitrogen, creatinine
3. Screening for latent infections, in particular hepatitis B and C and tuberculosis (T-spot test). Initiation of cladribine should be delayed until the infection is fully controlled
4. Testing for anti-VZV antibodies in patients without a history of chickenpox or without varicella zoster virus (VZV) vaccine. VZV vaccination of antibody-negative patients should be considered prior to treatment initiation.

**II. During the first and up to 6 months after the last (second) treatment cycle:**
1. Complete blood count with differential:
   a) at 2 and 6 months of treatment initiation in each year of treatment
   b) Before initiating cladribine in year 2, the lymphocyte counts should be at least 800 cells/mm³. If necessary, the year 2 treatment cycle can be delayed for up to 6 months to allow recovery of lymphocytes.

Baseline MRI for evaluation of the risk of development of PML is strongly recommended prior to initiation of second-line therapies and in patients switching to another first-line therapy.

**Conversion** from relapsing-remitting to secondary progressive multiple sclerosis is defined in the absence of relapses, and progressive deterioration of patient’s condition by more than 1 point in EDSS score within 1 year.

Interferons beta-1b therapies (Betaferon, Extavia®) are used for **treatment of the secondary, progressive** phase of the disease in patients with frequent relapses and disability progression (**progressive-remitting MS**). Treatment is given to patients with more rapid progression; pharmacological treatment is not required in slow disease progression.

**Criteria for multiple sclerosis treatment in SPMS patients with frequent superimposed relapses**

**I. Inclusion criteria:**
1. Multiple sclerosis diagnosed according to 2010 revised diagnostic criteria
2. Ages of 18 to over 60
3. EDSS score of up to 4,0

**II. Exclusion criteria**
1. Concomitant chronic diseases which shorten life expectancy (alcohol abuse, dementia, psychotic disorders, active malignancies)
2. Patients with severe depression and suicide attempts during treatment;
3. Pregnancy

**III. Treatment is not administered or if initiated should be discontinued in:**

1. Pregnancy
2. Serious adverse drug reactions
3. Lack of clinical efficacy of the therapy – progressive deterioration of patient's condition by more than 1 point in EDSS score within 1 year
4. High level of non-adherence to the therapy
5. Disability progression to EDDS = 5
6. Reaching the age of 59 years, and the absence of disease activity during the last 2 years

In patients with secondary progressive multiple sclerosis and frequent superimposed relapses the neurologist must decide for initiation of:

1. Interferon beta-1b therapy (Betaferon, Extavia®)
2. Symptom management.

**Treatment of primary progressive MS** is symptomatic as currently there are no approved medications for the treatment of this form of the disease.

**Stem cell transplantation** is used to achieve rapid, complete and long-lasting immunosuppression. Peripheral blood stem cell transplantation is performed after development of deep immunosuppression. It might be efficient in patients with malignant MS, however its toxicity with a mortality rate of 5-10% should be considered. To date, there have been few published studies with up to 2-year follow-up in which 80% of patients with relapsing-remitting MS were relapse-free compared to only 40% of patients with primary progressive MS. Maintenance immunosuppressive therapy is not required. The use of stem cell transplantation in clinical practice requires studies with significantly longer duration. The Movement Disorders and Multiple Sclerosis Society, and the Bulgarian Society of Neurology do not recommend this therapy until its efficacy and safety have been established in controlled studies.

**Percutaneous transluminal endovascular angioplasty or extracranial venous stenting** for treatment of chronic cerebrospinal venous insufficiency should not be used in patients with multiple sclerosis. Chronic cerebrospinal venous insufficiency has no role in the pathogenesis of multiple sclerosis.

Patients are admitted by a neurologist to a neurological unit or outside UCDM-MS for:
- Relapse management
- Pharmacological treatment initiation outside of clinical relapse
- Onset of other threatening symptoms.

**The neurologist at UCDM-MS should see the patient once every 6 months whenever deterioration occurs, and monitor for signs of:**

- Onset of new relapse
- Progressive neurological decline with an increase in EDSS score of 1 or more points sustained over one year
- Increased relapse rate – more than 2 attacks per year
- Treatment side effects outside of clinical relapse
- Treatment efficacy outside of clinical relapse
- Depression, fatigue, cognitive, sexual or pelvic floor disorders
- Need for symptomatic management

**The general practitioner should:**

- Observe the patient for signs of somatic disease and treatment-related complications
- Manage any symptom complications

**The optimisation of treatment control** requires clinical assessment of patients at least once every 6 months. Follow-up evaluations should include relapse rate, severity and duration of relapses and degree of recovery from the relapse. This allows for the patient's optimal response to the administered immunomodulatory therapy to be determined. A reduction in relapse rate by 30% to 45% from baseline is a criterion for treatment efficacy. Evaluation of treatment efficacy can be performed 6 months after initiation of therapy. Relapses have different significance for patients depending on the associated clinical symptoms. Signs of motor and cerebellar system dysfunction and symptoms of pelvic bowel and bladder disorders, particularly with involvement of several systems during relapse, are predictors of poorer outcome. Relapses requiring corticosteroid treatment are significant. Relapses in the early stages of the disease that are unresponsive to corticosteroid treatment are also associated with poorer prognosis. Refractoriness to steroid therapy is common in more advanced stages of the disease. An immunomodulatory therapy may be considered not sufficiently effective if recovery from previous relapse is incomplete or lasts several months. Disability progression measured by EDSS (Appendix 6) is another sign of lack of efficiency of
immunomodulatory therapy. Treatment efficacy evaluation is also based on MRI findings. This includes evidence of new or enlarged T1 and T2 lesions, gadolinium-enhanced lesions, brain atrophy and total MRI burden of the disease. Assessments of cognitive function, fatigue, depression, social activities and quality of life are also important in determining the efficacy of treatment. Based on evidence for immunomodulatory therapy impact on cognitive disturbances, cognitive decline is considered an indicator of **suboptimal treatment efficacy**.

<table>
<thead>
<tr>
<th>Treatment should be reconsidered in evidence of worsening of relapses, disability progression and MRI findings (Appendix 6):</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Evidence of low level of significance for all three parameters</td>
</tr>
<tr>
<td>• Evidence of moderate level of significance for 2 parameters</td>
</tr>
<tr>
<td>• Evidence of high level of significance for one parameter</td>
</tr>
<tr>
<td>• Treatment of a patient with relapsing-remitting or secondary progressive MS should be continued until disability EDSS score 5 is reached</td>
</tr>
<tr>
<td>• After this degree of disability relapse rate reduction has no impact on disability progression</td>
</tr>
</tbody>
</table>

Conventional treatment is not efficient in a certain portion of patients. Currently used medications mainly address inflammation and have a moderate effect on the relapse rate. In one-third of patients on average, the relapse rate remains unchanged. Better clinical outcomes observed in patients with more relapses are explained with more prominent inflammatory rather than degenerative component of the disease. No drugs are available yet that can influence the neurodegenerative process. If case of therapy inefficiency, the patient should be offered enrolment in clinical trials of new drugs.

To avoid any disappointment, it should be explained to the patients that the treatment aims at reducing the rate of subsequent relapses, but it does not have any effects on the current symptoms of the disease. Reduction in the relapse rate by 30%, and possible delay of disability progression is what can be expected.

**Symptomatic treatment** is necessary because new symptoms appear, while old symptoms become worse, which has a negative impact on the patients' quality of life. In order to determine whether a certain symptom has to be treated, symptoms have to be classified into degrees such as mild, moderate and severe. Mild symptoms are those that do not interfere with the patient's everyday activities and do not require treatment. Moderate symptoms interfere with every day and social activities of the patient, and cause discomfort. Such symptoms require pharmacological treatment. Severe symptoms lead to disability, and limit to a serious extent the patient’s everyday activity. These
symptoms usually cannot be managed by pharmacological treatment and require more specific measures and care.

*Fatigue* is managed by different non-pharmacological methods, such as aerobic exercises, physical therapy, behavioural therapy and others. The administration of amantadine – 200 mg daily, fluoxetine – 10 to 40 mg daily, and modafinil – 100-400 mg in the morning relieves fatigue.

*Cognitive disorders* are managed with donepezil 10 mg daily, although treatment efficacy is relatively low.

*Affective disorders* – depression is managed with tricyclic antidepressants and serotonin and noradrenaline reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs). Lithium and anticonvulsants are used for the treatment of bipolar disorders and tricyclic antidepressants (amitriptyline 25 mg daily) – for the management of pathological laughter and crying.

*Pain syndromes* are relieved using tricyclic antidepressants and SNRIs (amitriptyline, venlafaxine, moclobemide, mirtazapine, duloxetine, milnacipran), anticonvulsants (carbamazepine, gabapentin, phenytoin, topiramate, gabapentin and pregabalin) and skeletal muscle relaxants.

*Muscle weakness* is best managed by physical therapy and physical exercises. Patients should be encouraged to be physically active. Preventive measures to minimize muscle contracture development and preserve passive joint movements of affected limbs are recommended.

*Gait disturbances* are improved using the potassium channel blocker fampridine (Fampyra®). By blocking potassium channels, fampridine reduces the leakage of ionic current through these channels which prolongs re-polarization and enhances action potential formation in demyelinated axons. It is thought that by enhancing action potential formation, more impulses might be conducted in the central nervous system. Fampyra® should be prescribed and used under the supervision of a clinician experienced in the treatment of multiple sclerosis. The recommended dose is one 10 mg tablet twice daily. Tablets should be taken without food. The initial prescription should be for no more than 2 weeks of therapy, and should be followed by evaluation of the clinical efficacy of the drug, determined by a T25FW (timed 25-feet walk) test. Fampyra® should be discontinued if there is no benefit or worsening is reported by the patient.

*Spasticity (increased muscle tone)* is well managed by physical therapy and muscle relaxants. Tizanidine (Sirdalud®) – up to 24 mg daily, and baclofen – up to 70 mg daily can be used. *Vertigo* might be a symptom of relapse in which case it can be well managed by a course of corticosteroids. In case it is a residual symptom, dimenhydrinate 75-150 mg/day, betahistine 48 mg/day, and combined therapy with cinnarizine/dimenhydrinate (Arlevert®), 3x1 tablet daily can be used.

*Tremor* is difficult to manage but in some cases treatment with clonazepam 2-4 mg/day, propranolol 50-100 mg, isoniazid 1,200 mg/day, glutethimide 1,000-4,000 mg/day or primidone 250 mg/day is effective.
**Paroxysmal symptoms** respond to anticonvulsants, tricyclic antidepressants and benzodiazepines. Carbamazepine (up to 1,200 mg daily) is the drug of choice. Epileptic seizures can be well managed by the use of conventional anticonvulsants such as carbamazepine and phenytoin, and valproates.

**Pelvic floor disorders** can seriously affect the quality of patients’ lives. Overactive bladder is improved by anticholinergic agents (oxybutynin 10 mg daily or tolterodine (Detrusitol®) 4 mg daily), the β3-adrenergic receptor agonist mirabegron (Betmiga®) 25-50 mg and tricyclic antidepressants, while intermittent catheterisation is a method of choice in the treatment of underactive bladder. In less severe cases vibration devices are used on the abdominal wall above the bladder to stimulate bladder emptying. The patient should be observed for symptoms of incontinence or urinary infections and if necessary antibiotic treatment should be considered. Patients with nocturia are prescribed desmopressin nasal spray (10-40 µg per night), an antidiuretic hormone, which reduces urination for 6-8 hours, but may cause hyponatremia. In patients with detrusor sphincter dyssynergia skeletal muscle relaxants and alpha-2 agonists can be used.

**Sexual disorders** are treated with antidepressants and erectile dysfunction is managed through administration of a phosphodiesterase type 5 inhibitor – sildenafil (Viagra®) 50 to 100 mg, vardenafil (Levitra®) 5-10 mg orally, 1 hour prior to sexual activity, and tadalafil (Cialis®) 20 mg.

**Gastrointestinal disorders** (constipation) require complex management. Above all, it has to be clarified whether the constipation is caused by any of the medications received and if so, their doses should be reduced. Increased physical activity, dietary changes by eating fibre-rich food, and the avoidance of chocolate products, hydration and warm drinks for stimulation of gastrointestinal reflexes are recommended. If dietary measures are insufficient mild laxatives may be used.

**Dysphagia** is managed by dietary modification and changes in the way of eating. In severe cases a nasogastric tube might be used.

**Visual disorders** (diplopia) are corrected with prism eyeglasses. Nystagmus is treated with baclofen, clonazepam, scopolamine, gabapentin and other drugs.

**Respiratory disorders** are managed through treatment of respiratory infections, regulation of body temperature to improve axonal conductivity and vaccines for anti-flu prophylaxis.

**Rehabilitation** is a very important part of health care delivery for patients with multiple sclerosis. They should be referred to physical therapy and rehabilitation when their everyday activities are already restricted and symptomatic management is no longer effective. At a certain time of his/her life the patient shall need crutches, a walking aid or a wheelchair, which requires a thorough assessment by a physiotherapy specialist.

**Comprehensive care** in MS patients has certain specific features.
Fever and infections should be prevented and promptly treated. Demyelinated fibres are extremely sensitive to minimal changes in body temperature or mild acidosis. Exposure to high temperatures on beaches, in saunas, tubs or swimming pools or even a slight elevation of 1-2 degrees in body temperature caused by infection may lead to disease deterioration. This is the reason for frequent relapses occurring even after mild respiratory infections. Management of fever in infections is extremely important and contributes significantly to the improvement of neurological symptoms.

Surgical interventions and anesthesia have a minimal impact on patient’s condition, so they can be used if clinically indicated. Intrathecal and spinal anesthesia should be avoided; epidural anesthesia is well tolerated.

During pregnancy the risk of relapse decreases dramatically, especially during the third trimester, as corroborated by MRI findings. The risk increases considerably during the postpartum period. If the two periods are considered together, pregnancy carries no real risk of deterioration. Female patients with multiple sclerosis not only have no contraindications to pregnancy and delivery, but also disease prognosis is not worsened but rather improved by pregnancy. The risk of disease conversion to secondary progressive form is decreased. However, prognosis in patients who have already progressed to secondary progressive form of the disease is not so favourable. There is no evidence to suggest that MS affects in any way fertility, conception, fetal viability or birth. No increased risk of ectopic pregnancy, spontaneous abortion, stillbirth and congenital malformations has been observed. The only consideration that may need to be made in pregnancy planning is the patient’s disability which might make child-bearing difficult. Children of a parent with MS have a low genetic risk of MS (about 3% to 5%), however in the very rare cases of both parents having MS, the risk will increase to 31%.

All disease-modifying drugs should be stopped prior to planned pregnancy because they are contraindicated during this period. In contrast to beta-interferons, glatiramer acetate is not associated with increased risk of spontaneous abortion, so it can be used at the clinician's discretion during pregnancy.

There is no evidence for teratogenic effects of beta-interferons and glatiramer acetate, so mutagenicity is not increased even after long-term exposure and there is no risk for the child.

Both glatiramer acetate and beta-interferon are large molecules and would not be expected to excrete in breast milk, so they are probably safe during breastfeeding.

While on treatment with fingolimod, and for 2 months after its discontinuation women should not become pregnant because of a risk to the fetus. Patients have to use effective methods of contraception. There is no data to suggest that fingolimod would be associated with an increased risk of reduced fertility. Fingolimod should not be used during lactation.
Dimethyl fumarate is not associated with increased risk of reduced fertility. Treatment should be discontinued 1 month prior to conception. Dimethyl fumarate should be avoided during lactation.

Teriflunomide is contraindicated in pregnancy due to teratogenicity. The risk of male-mediated embryo-fetal toxicity through teriflunomide treatment is considered low. Teriflunomide plasma concentration has to be measured before the woman attempts a pregnancy. In case of unplanned pregnancy an accelerated elimination procedure with cholestyramine or active charcoal is required. Teriflunomide is not recommended during lactation.

Natalizumab should be stopped 2 months prior to pregnancy. Not recommended during lactation.

Pregnancy should be avoided for 4 months after the last infusion of alemtuzumab. The thyroid function should be monitored for at least 4 years after the last infusion because of its connection to the fetal wellbeing. Breast feeding should be stopped during each course of treatment with alemtuzumab and for 4 months thereafter.

Cladribine is contraindicated in pregnant women. In women of childbearing potential, pregnancy must be excluded before initiation of cladribine in year 1 and year 2, and prevented by using effective contraception during cladribine treatment and for at least 6 months after the last dose. Women who become pregnant under therapy with cladribine must discontinue treatment. Male patients should take precautions to prevent pregnancy of their female partner during cladribine treatment and for at least 6 months after the last dose. Breast-feeding is contraindicated during treatment with cladribine and for 1 week after the last dose.

The use of corticosteroids or other drugs for symptomatic management should also be discontinued during pregnancy. Short courses (3-5 days) of prednisolone or methylprednisolone treatment can be administered for relapse management only during the second and third trimesters of pregnancy.

There is no data to suggest a short-term increase in the risk of rebound activity following discontinuation of disease modifying drugs, while on the other hand the patient will enter a period when the disease is suppressed by the pregnancy. After delivery, however when the risk of relapses increases, immediate initiation of DMT is advised. In such cases breast-feeding is not recommended and the baby should be fed by formula feeding. If the patient does not receive medications, breastfeeding not only should not be avoided, but it might also prevent an increase in disease activity.

There are no specific requirements for the childbirth method except for unconfirmed considerations about avoiding spinal anesthesia.

The use of oral contraceptives does not affect the disease course, so they are not contraindicated in multiple sclerosis. Exceptional cases are patients with a rare form of multiple sclerosis, whose relapses are closely related to the menstrual cycle and contraception, and in such
cases oral contraception may have a beneficial effect on the disease. There are no contraindications to hormone replacement therapy in menopausal women either. HRT has a beneficial effect on disease symptoms which tend to become worse during menopause.

**Vaccinations** are safe in MS patients. Some data even suggest that flu vaccine and antitubercular BCG vaccine reduce relapse rate. Exceptions are vaccinations during relapses or in very active disease stages. Patients are recommended to receive influenza vaccines as 25% of all relapses are caused by flu or other viral infections. All vaccinations are safe in patients receiving DM therapies as well. Immunizations are also safe in patients receiving immunosuppressive therapy with the exception of live virus vaccines (varicella, measles, rubella, and mumps).

**Nutrition and physical activity** have been largely studied. Normal physical activity, aerobic exercises and sports enjoyed by the patient are recommended but overheating, dehydration, excessive exertion and activities associated with potential risk of injury should be avoided. Elevation of body temperature during physical activity may cause transient symptoms (paresthesia, blurred vision) that do not lead to sustained complications and are not a contraindication to sporting activities. Swimming is not contraindicated if the water is warm enough. Patients with lower extremity weakness can participate in sports engaging the upper limbs (yoga).

There is no evidence that any of the proposed diets has a beneficial effect on the course of the disease. A low-fat diet is very popular but its clinical benefit has not been confirmed yet. Still, patients should be recommended a diet rich in polyunsaturated fatty acids and vitamin D, and poor in animal fats, as well as cessation of tobacco smoking.

**The social and psychological aspects** of the disease are of crucial importance. Initially, when patients learn about their poor prognosis and uncertain future, they need emotional support. With the progression of their disability however, patients can no longer keep up to their habitual duties, and eventually quit working. Later on, they become dependent on caregivers' help in their everyday activities. They are often abandoned by their partners and have to take care of themselves alone. They are faced with different problems in the course of the disease stages and must be prepared by timely education.

**The education of patients** should start with their being diagnosed. The patient should be made familiar with the nature of the disease, and the chances for a favourable outcome. Patients should also be advised to observe proper hygiene and dietary regime, and avoid “alternative” methods of treatment. In the beginning of the disease patients should not be encouraged to join “MS societies” because they are likely to meet many patients with severe neurological deficits there, for which they are not emotionally prepared yet. Most brochures are also intended for patients in the advanced stages of the disease. The support a patient could get at a later stage from different associations and communities is of extreme importance.
Appendix 1. Clinical Course Forms of MS, Depending on Time Profile

Relapsing-remitting MS

Secondary progressive MS
Primary progressive MS

Disability

Time
### Appendix 2. 2010 Revised McDonald Diagnostic Criteria for MS

<table>
<thead>
<tr>
<th>Clinical symptoms</th>
<th>Additional data needed for MS diagnosis</th>
</tr>
</thead>
</table>
| − 2 or more attacks;  
− objective clinical evidence of 2 or more lesions; or  
− objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack | None. Clinical evidence alone will suffice; However, MRT is recommended to meet the criteria. If there is a Cerebrospinal fluid testing, it must also meet the criteria. |
| − 2 or more attacks;  
− objective clinical evidence of 1 lesion | Dissemination in space, demonstrated by:  
− ≥1 T₂ lesion in at least 2 or 4 MS typical regions (periventricular, juxtacortical, infratentorial, spinal cord); OR  
− Await further clinical attack implicating a different CNS site |
| − 1 attack;  
− objective clinical evidence of 2 or more lesions | Dissemination in time, demonstrated by:  
− Simultaneous asymptomatic gadolinium-enhanced and non-enhancing lesions at any time; OR  
− A new T₂ and/or gadolinium-enhanced lesion(s) on follow-up MRI, irrespective of its timing; OR  
− Await a second clinical attack |
| − 1 attack;  
− objective clinical evidence of 1 lesion (clinically isolated syndrome) | Dissemination in time and space, demonstrated by:  
**Dissemination in space:**  
− ≥1 T₂ lesion in at least 2 or 4 MS typical regions (periventricular, juxtacortical, infratentorial, spinal cord); OR  
− Await a second clinical attack implicating a different CNS site;  
**Dissemination in time:**  
− Simultaneous asymptomatic gadolinium-enhanced and non-enhancing lesions; OR  
− A new T₂ and/or gadolinium-enhanced lesion(s) on follow-up MRI, irrespective of its timing; OR  
− Await further clinical attack |
| Gradual progression of neurological symptoms, suggesting MS (primary progressive MS) | 1 year of disease progression (retrospective or prospective) AND at least 2 out of 3 criteria:  
1. **Dissemination in space** in the brain based on ≥1 T₂ lesion MS typical regions (periventricular, juxtacortical, infratentorial); OR  
2. **Dissemination in space** in the spinal cord based on ≥2 T₂ lesions; OR  
3. Positive CSF (oligoclonal fractions and/or elevated IgG index) |
### Appendix 3. Corticosteroid Treatment of MS Relapses

<table>
<thead>
<tr>
<th>Corticosteroid – Dosage forms</th>
<th>Administration</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Methylprednisolon</strong>&lt;br&gt;amp. 125 mg; 250 mg</td>
<td>500-1,000 mg i.v. in serum glucose 500 ml over 1-1.5 hours for 5 days</td>
<td>Pulse therapy – for 5 days in relapse and optic neuritis&lt;br&gt;In very severe (with possible brain stem symptoms) attack and acute MS 1,000 mg i.v.</td>
</tr>
<tr>
<td><strong>2. Methylprednisolon</strong>&lt;br&gt;amp. 20 mg; 40 mg</td>
<td>80 mg i.m. for 3 days&lt;br&gt;60 mg a total of 12 days&lt;br&gt;40 mg in the morning&lt;br&gt;20 mg single dose</td>
<td>I option – oral tapering following intravenous pulse therapy</td>
</tr>
<tr>
<td><strong>3. Prednisolone F</strong>&lt;br&gt;tabl. 0.5 mg</td>
<td>12 tabl. = 6 mg&lt;br&gt;10 tabl. = 5 mg for 2-3 days&lt;br&gt;8 tabl. = 4 mg in the morning&lt;br&gt;6 tabl. = 3 mg single dose&lt;br&gt;4 tabl. = 2 mg after breakfast&lt;br&gt;2 tabl. = 1 mg</td>
<td>II option – oral tapering following intravenous pulse therapy</td>
</tr>
<tr>
<td><strong>4. Prednisolone</strong>&lt;br&gt;tabl. 5 mg</td>
<td>12 tabl. = 60 mg&lt;br&gt;10 tabl. = 50 mg for 2-3 days&lt;br&gt;8 tabl. = 40 mg in the morning&lt;br&gt;6 tabl. = 30 mg single dose&lt;br&gt;4 tabl. = 20 mg after breakfast&lt;br&gt;2 tabl. = 10 mg</td>
<td>III option – oral tapering following intravenous pulse therapy</td>
</tr>
</tbody>
</table>
## Appendix 4. Symptomatic Pharmacological Treatment in Multiple Sclerosis

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Drug, pharmaceutical form, mg</th>
<th>Daily dose, mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Muscle tone spasticity</strong></td>
<td>Tizanidine (Sirdalud) tabl. 2, 4</td>
<td>2-32</td>
</tr>
<tr>
<td></td>
<td>Backlofen tabl. 10, 25</td>
<td>50-100</td>
</tr>
<tr>
<td><strong>Intention tremor</strong></td>
<td>Isoniazid (Rimicid) tabl. 100 mg</td>
<td>800-1,200</td>
</tr>
<tr>
<td></td>
<td>β-blockers (Propranolol) tabl. 25 and 40 mg</td>
<td>50-120</td>
</tr>
<tr>
<td></td>
<td>Primodone (Mysolin, Liskantin) tabl. 250 mg</td>
<td>125-750</td>
</tr>
<tr>
<td></td>
<td>Glutethimide tabl. 250 mg</td>
<td>1,000-4,000</td>
</tr>
<tr>
<td><strong>Gait disturbances</strong></td>
<td>Fampridine (Fampyra) tabl. 10</td>
<td>20</td>
</tr>
<tr>
<td><strong>Pelvic floor disturbances</strong></td>
<td>Galanthamin (Nivalin) tabl. 5; 10; amp. 2.5; 5</td>
<td>10-30</td>
</tr>
<tr>
<td>Imperative urges and incontinence</td>
<td>Nivabex sir. fl.</td>
<td>2-4</td>
</tr>
<tr>
<td></td>
<td>Tolterodine (Detrusitol) tabl. 1; 2</td>
<td>10-20</td>
</tr>
<tr>
<td></td>
<td>Oxybutynin (Driptane) tabl. 5; 10</td>
<td>1-4 nasal drops</td>
</tr>
<tr>
<td></td>
<td>Desmopressin (Adiuretin) fl. 500 μg/5ml</td>
<td>2-3 times daily</td>
</tr>
<tr>
<td></td>
<td>Mirabegron (Betmiga) 25; 50</td>
<td>25-50</td>
</tr>
<tr>
<td><strong>Urinary retention</strong></td>
<td>Baclofen tabl. 10; 25</td>
<td>20-40</td>
</tr>
<tr>
<td></td>
<td>Diazepam tabl. 5; 10</td>
<td>10-15</td>
</tr>
<tr>
<td><strong>Nystagmus</strong></td>
<td>Baclofen tabl. 10; 25</td>
<td>50-100</td>
</tr>
<tr>
<td></td>
<td>Clonazepam (Rivotril) tabl. 0.5; 2</td>
<td>0.5-4.0</td>
</tr>
<tr>
<td></td>
<td>Gabapentin (Neurontin) tabl. 300; 400; 800; caps. 600</td>
<td>2-3 g</td>
</tr>
<tr>
<td><strong>Pain, paresthesia and paroxysmal attacks</strong></td>
<td>Amitriptyline dr. 25 mg</td>
<td>25-75</td>
</tr>
<tr>
<td></td>
<td>Gabapentin (Neurontin) tabl. 300; 400; 800; caps. 600</td>
<td>2-3 g</td>
</tr>
<tr>
<td></td>
<td>Pregabalin (Lyrica, Brieka) caps. 25; 50; 75; 100; 150; 200; 300</td>
<td>300-600</td>
</tr>
<tr>
<td></td>
<td>Carbamazepine (Tegretol) tabl. 200</td>
<td>200-1,200</td>
</tr>
<tr>
<td></td>
<td>Clonazepam (Rivotril) tabl. 0.5; 2</td>
<td>0.5-4.0</td>
</tr>
<tr>
<td></td>
<td>Phenytoin (Epilan, Phenhydan) tabl. 10</td>
<td>300-400</td>
</tr>
<tr>
<td></td>
<td>Lamotrigine (Lamictal) tabl. 5; 25; 50; 100</td>
<td>100-300</td>
</tr>
<tr>
<td></td>
<td>Topiramate (Topamax) tabl. 50; 100; 200; 300; 400</td>
<td>100-200</td>
</tr>
<tr>
<td><strong>Fatigue</strong></td>
<td>Amantadine sulfat (PK-Merz) tabl. 100</td>
<td>200-300</td>
</tr>
<tr>
<td></td>
<td>Modafinil (Aspendos) tabl. 100</td>
<td>100-400</td>
</tr>
<tr>
<td><strong>Depression and neuropathic pain</strong></td>
<td>Amitriptyline dr. 25</td>
<td>25-75</td>
</tr>
<tr>
<td></td>
<td>Venlafaxine (Laroxine, Effectin) tabl. 75; 150</td>
<td>75-300</td>
</tr>
<tr>
<td></td>
<td>Moclobemide (Aurorix) tabl. 150</td>
<td>150-300</td>
</tr>
<tr>
<td></td>
<td>Mirtazapine (Remirta) tabl. 30; 45</td>
<td>30-60</td>
</tr>
<tr>
<td></td>
<td>Duloxetine (Dulsevia, Aritavi) caps. 30; 60</td>
<td>30-60</td>
</tr>
<tr>
<td></td>
<td>Milnacipran (Ixel) caps. 25; 50</td>
<td>25-50</td>
</tr>
<tr>
<td>Condition</td>
<td>Medication</td>
<td>Dose</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>Galanthamin (Nivalin) tabl. 5; 10&lt;br&gt;Donepezil (Aricept) tabl. 5; 10</td>
<td>10-30&lt;br&gt;5-10</td>
</tr>
<tr>
<td>Vertigo</td>
<td>Dimenhydrinat (Dimenhydrinat) tabl. 50&lt;br&gt;Betahistine (Betaser, Vertisan) tabl. 16&lt;br&gt;Cinnarizine/Dimenhydrinat (Arlevert 20 mg/40 mg)</td>
<td>75-150&lt;br&gt;48&lt;br&gt;60 mg/120 mg</td>
</tr>
</tbody>
</table>
### Appendix 5. Levels of Clinical Significance by Therapy Efficacy Criteria

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Low significance</th>
<th>Moderate significance</th>
<th>High significance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Relapses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frequency/severity</td>
<td>1 mild relapse per year</td>
<td>1 moderate relapse per year</td>
<td>More than 1 moderate or 1 severe relapse per year</td>
</tr>
<tr>
<td>Recovery</td>
<td>Slow recovery following corticosteroid treatment</td>
<td>Slow recovery following corticosteroid treatment</td>
<td>Incomplete recovery following corticosteroid treatment</td>
</tr>
<tr>
<td><strong>Progression</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDSS&lt;3.5</td>
<td>&lt; 2-point change</td>
<td>2-point change</td>
<td>&gt; 2-point change</td>
</tr>
<tr>
<td>EDSS&gt;4</td>
<td>&lt; 1-point change</td>
<td>1-point change</td>
<td>&gt; 1-point change</td>
</tr>
<tr>
<td>Clinical progression</td>
<td>No motor symptoms; minimal sensorial symptoms</td>
<td>Moderate motor symptoms; cognitive or more pronounced sensory symptoms</td>
<td>Pronounced motor, cognitive and other symptoms</td>
</tr>
<tr>
<td><strong>MRI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New gadolinium-enhanced lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New T&lt;sub&gt;2&lt;/sub&gt; lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enlarging T&lt;sub&gt;2&lt;/sub&gt; lesions (burden)</td>
<td>Changes in 2 categories</td>
<td>Changes in 3 categories</td>
<td>Changes in &gt; 3 categories</td>
</tr>
<tr>
<td>New T&lt;sub&gt;1&lt;/sub&gt; lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enlarging T&lt;sub&gt;1&lt;/sub&gt; lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increasing atrophy</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 6.

J. F. Kurtzke Scale (1983) for Quantitative Assessment of Neurological Impairment in Multiple Sclerosis – Expanded Disability Status Scale (EDSS)

A. Pyramidal Functions:
0 – Normal;
1 – Abnormal signs without disability (asymmetrical hyperreflexia, decreased or missing abdominal reflexes, pathological reflexes from the Babinski group, etc.);
2 – Minimal disability (latent paresis);
3 – Mild or moderate paraparesis or hemiparesis; severe monoparesis;
4 – Marked paraparesis or hemiparesis; moderate quadriparesis; or monoplegia;
5 – Paraplegia, hemiplegia, or marked quadriparesis;
6 – Quadriplegia;
V – Unknown.

B. Cerebellar Functions:
0 – Normal;
1 – Abnormal signs without disability (coordination disorders seen only in coordination testing, no gait disturbance or interference with everyday activities);
2 – Mild truncal or limb ataxia;
3 – Moderate truncal or limb ataxia;
4 – Severe ataxia in all limbs, but with certain effective movement;
5 – Unable to perform coordinated movements due to ataxia;
V – Unknown;
X – Placed after each number to denote that limb weakness interferes with testing.

C. Brainstem Functions:
0 – Normal;
1 – Abnormal signs without disability (e.g., listlessness sensory symptoms);
2 – Moderate nystagmus or other mild disability;
3 – Severe nystagmus, marked extraocular weakness, or moderate disability of other cranial nerves;
4 – Marked dysarthria or other marked disability (facial diplegia or ophthalmoplegia);
5 – Inability to swallow or speak;
V – Unknown.

D. Sensory function:
0 – Normal;
1 – Vibration or figure-writing decrease only in 1-2 limbs;
2 – Mild decrease in touch, pain or position sense, and/or moderate decrease in vibration in 1-2 limbs; or vibratory decrease alone in three or four limbs;
3 – Moderate decrease in touch, pain or position sense, and/or loss vibration in one or two limbs; or mild decrease in touch, pain and/or moderate decrease in all proprioceptive tests in three or four limbs;
4 – Marked decrease in touch or pain or loss of proprioception, alone or combined, in one or two limbs; or moderate decrease in touch, pain and/or severe proprioceptive decrease in more than two limbs;
5 – Loss of sensation in one or two limbs; or moderate decrease in touch, pain and/or loss of proprioception for most of the body below the head;
6 – Sensation essentially lost below the head;
V – Unknown.

**E. Bowel and Bladder Function:**

0 – Normal;
1 – Mild urinary hesitance, urgency, rarely retention;
2 – Moderate hesitance, urgency, retention or rare urinary incontinence;
3 – Frequent urinary incontinence;
4 – In need of almost constant catheterization;
5 – Loss of bladder function;
6 – Loss of bladder and bowel function;
V – Unknown.

**F. Visual Function:**

0 – Normal;
1 – Scotoma with visual acuity (corrected) better than 20/30;
2 – Worse eye with scotoma with maximal visual acuity (corrected) of 20/30-20/59;
3 – Worse eye with large scotoma, or moderate decrease in fields, but with maximal visual acuity (corrected) of 20/60-20/99;
4 – Worse eye with marked decrease of fields and maximal visual acuity (corrected) of 20/100-20/200; grade 3 plus maximal acuity of better eye of 20/60 or less;
5 – Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 plus maximal acuity of better eye of 20/60 or less;
6 – Grade 5 plus maximal visual acuity of better eye of 20/60 or less;
V – Unknown;
X – Added to grades 0 to 6 in presence of temporal pallor.
**G. Mental Functions:**

0 – Normal;
1 – Mood alteration only (euphoria or depression);
2 – Mild decrease in mentation with regard to abstract thinking or mathematical operations;
3 – Moderate decrease in mentation, disturbance in judgments and conclusions;
4 – Marked decrease in mentation with certain disorientation;
5 – Dementia;
V – Unknown.

**H. Other functions:**

0 – Normal;
1 – Define finding if any;
V – Unknown.
Kurtzke Expanded Disability Status Scale (1986)

0 – Normal neurological exam (all grade 0 in all functional system (FS) scores); possible mental grade 1.

1 – No disability, minimal signs in one FS (i.e., grade 1) without mental grade 1; all grade 0 in remaining systems.

1.5 – No disability, minimal signs in more than one FS (more than 1 FS grade 1; with or without mental grade 1).

2 – Minimal disability in one FS (one FS grade 2, others 0 or 1).

2.5 – Minimal disability in two FS (two FS grade 2, others 0 or 1).

3– Moderate disability in one FS (one FS grade 3, others 0 or 1) or mild disability in three or four FS (three or four FS grade 2, others 0 or 1) though fully ambulatory.

3.5 – Fully ambulatory but with moderate disability in one FS (one FS grade 3) and one or two FS grade 2; or two FS grade 3 (others 0 or 1) or five grades 2 (others 0 or 1).

4 – Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe disability consisting of one FS grade 4 (others 0 or 1), or combination of lesser grades exceeding limits of previous steps; able to walk without aid or rest some 500 meters.

4.5 – Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance; characterized by relatively severe disability usually consisting of one FS grade 4 (others 0 or 1) or combinations of lesser grades exceeding limits of previous steps; able to walk without aid or rest some 300 meters.

5 – Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily activities (one FS grade 5, others 0 or 1; or combinations of lesser grades usually exceeding specifications for step 4.0).

5.5 – Ambulatory without aid for about 100 meters; disability severe enough to preclude full daily activities; (one FS grade 5, others 0 or 1; or combinations of lesser grades usually exceeding specifications for step 4.0).

6– Intermittent or unilateral constant assistance (cane or crutch) or intermittent bilateral intermittent assistance required to walk about 100 meters with or without resting; (more than two FS grade 3+).

6.5 – Constant bilateral assistance (canes, crutches) required to walk about 20 meters without resting; (more than two FS grade 3+).

7 – Unable to walk beyond 5 meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a
day; (FS equivalents are combinations with more than one FS grade 4+; very rarely pyramidal grade 5 alone).

7.5 – Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot carry on in standard wheelchair a full day; may require motorized wheelchair; (FS equivalents are combinations with more than one FS grade 4+).

8 – Essentially restricted to bed or chair or perambulated in wheelchair; can move limbs and has effective use of arms; (FS equivalents are combinations, generally grade 4+ in several systems).

8.5 – Essentially restricted to bed; has some effective use of arm(s); (FS equivalents are combinations, generally 4+ in several systems).

9 – Helpless bed patient; can only communicate and swallow; (FS equivalents are combinations, mostly grade 4+).

9.5 – Totally helpless bed patient; unable to communicate effectively or swallow; (FS equivalents are combinations, almost all grade 4+).

10 – Death due to MS.